CA1135183A - Dispersed metal particle labelled assay - Google Patents

Dispersed metal particle labelled assay

Info

Publication number
CA1135183A
CA1135183A CA000331816A CA331816A CA1135183A CA 1135183 A CA1135183 A CA 1135183A CA 000331816 A CA000331816 A CA 000331816A CA 331816 A CA331816 A CA 331816A CA 1135183 A CA1135183 A CA 1135183A
Authority
CA
Canada
Prior art keywords
component
reagent
reaction
metal
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000331816A
Other languages
French (fr)
Inventor
Johannes H.W. Leuvering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzona Inc filed Critical Akzona Inc
Application granted granted Critical
Publication of CA1135183A publication Critical patent/CA1135183A/en
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553Metal or metal coated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • Y10S436/818Human chorionic gonadotropin

Abstract

ABSTRACT OF THE DISCLOSURE
The present invention relates to a method for the detection and/or determination of one or more components of the reaction between a specific binding protein and the correspond-ing bindable substance, in which one or more labelled compo-nents are used, that are obtained by coupling particles of a dispersion of a metal, metal compound or polymer nuclei, coated with a metal or metal compound, having a particle size of at least 5 nm, directly or indirectly to the desired component of said reaction. During the reaction or after an adequate reaction time, the physical properties and/or the amount of the metal and/or the formed metal containing agglomerate, is/are deter-mined in the test sample, or optionally after a separation of the bound and free metal-labelled components in one of the derived fractions by methods known by themselves.

Description

~13S~83 Ihe invention relates to a method for the detection and/or determination of one or more components of the reaction between a specific binding protein and the corresponding bind-able substance in an aqueous test sample, whilst applying the known binding affinity of such components for one another. Such components can be receptor proteins or immunochemical components, such as haptens, antigens or antibodies.
There are a large number of immunochemical methods known in which the presence of a certain immunological component is determined qualitatively and/or quantitatively by utilizing the mutual reactions between such components, such as the reac-tion between antigen and the antibody to that antigen.
In the study of such reactions for the demonstration and/or determination of the desired component, use may be made of aids, for example physical aids such as an electron micro-scope, or use may be made of a reagent which is provided with a marker or label which can be determined or demonstrated res-pectively in a lower concentration than the immunocomplex formed itself.
As examples of the category of qualitative immuno-chemical techniques there may be named the irnmunodiffusion method developed in 1948 by Ouchterlony and the variant thereof, immuno-electrophoresis, developed in 1953 by Grabar. The radial immunodiffusion method developed by Mancini in 1965 can be used quantitatively.
The immunodiffusion technique can be characterized as the placing of a thin layer of agar on a glass plate, after which two holes are made in the gel, a little distance apart.
The test liquid with antigen is introduced into one of the holes, and an antiserum into the other. As a result of the diffus;on of the two substances in the gel, these meet each other and c 1~35~33 form a visible precipitation line. Though this method is rela-tively simple, it does possess a nurnber of disadvantages, in particular the fact that the diffusion lasts for some time and that the results usually only provide a qualitative indication.
~he other immunochemical techniques also have their drawbacks, which apart from specific disadvantages generally consist of too long a duration for the test, a low sensitivity and/or the provision of only qualitative indications.
In addition to these non-labelled immunochemical techniques, a number of labelled techniques have been developed with the passage of the years, amongst which there may be named the haemagglutination test in which one of the components is bound to the surface of erythrocytes, the immunofluorescence technique, in which one of the components is labelled with a fluorescent compound (fluorophore), the radioimmunological de-termination developed by Yalow and Berson about 1959, in which, instead of a fluorophore, a radio-active atom or radio-active group is used as marker, and the most recent technique of enzyme-immunological determination, about which the first publications appeared in 1971 from two groups working independently, namely the Swedish investigators Engvall and Perlmann and the Dutch Schuurs and van Weemen. This last-named determination is in principle analogous to the known radio-immunological determina-tions, but with the difference that an enzyme is used as label instead of radio-active labelling, The much-used radio-irnmunological determination has indisputably great merit, but there are a number of substantial drawbacks associated with this method, such as the risk factor related to working with radio-active material, the high cost of reagents and apparatus, the poor stability of radio-active labelled reagents and the requirement that only qualified
-2-113~i83 personnel be allowed to perform these determinations.
The enzyme-immunological determination method does not possess these disadvantages, but it is nevertheless desir-able that new estimation techniques be developed which are even more sensitive, may be performed more rapidly, can be more rea-dily automated and/or make it possible to estimate more than one immunocomponent at the same time.
Furthermore, there is a strong need for a reliable and practical assay for receptor proteins.
me present invention relates to a process for the detection and/or determination of one or more components of the reaction between a specific binding protein and the correspond-ing bindable substance in an aqueous test sample, whilst apply-ing the known binding affinity of such components for one another, which is characterized by the fact that one or more labelled components, obtained by coupling directly or indirectly the desired component of said reaction to particles of an aqueous dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, having a particle size of at least 5 nm, w~.ereby during the reaction or after an adequate reaction time, optionally after separation of the bound and free labelled components, the physical properties and/or the amount of the metal and/or the formed metal containing agglo-merate is/are determined in the test sample or one of the derived fractions, by methods known by themselves, which deter-mination provides a qualitative and/or quantitative indication of the component or components to be detected and/or determined.
Ihe process according to the invention is especially suited for the estimation of immunochemical components, such as haptens, antigen~ and antibodies.
The particles of the aqueous dispersion of a metal,
-3-, : :

~1351~3 .

metal compound or polymer nuclei, coated with a metal or metal compound have a particle size of at least 5 nm and preferably 10 to 100 nm. Dispersions with a particle size of 10 to 100 nm of the dispersed phase are usually sols, but other types of disper-sions are not excluded.
me component to be labelled is coupled directly or indirectly to the dispersed particles. Under coupling is under-stood any chemical or physical binding, such as binding via co-valent bonds, via hydrogen bridges, polar attraction and ad-10 sorption.
Whenever the term "metal sol particles" is used inthe text which follows, this is understood to signify particles of a sol, consisting of a metal, a metal compound or polymer nuclei coated with a metal or metal compound.
The use of metal sol particles, in particular those of gold sols, which are covered on the surface with antibodies, for the demonstration of the distribution of an antigen over a cell surface by means of scanning electron microscopy, in which the metal sol particles are used as contrast enhancing label, has already been described some years ago (see article by M.
Horisberger in Experientia, pages 1147-1149, 15th October 1975), but the application of dispersed particles, preferably metal sol particles as a label for an immunological component for an in vitro qualitative and quantitative determination of immunological components, such as haptens, antigens and antibodies, in an aqueous test medium has not previously been reported and has surprisingly proved to be possible.
The metal sol particle immunochemical technique ac-cording to the invention which has been developed can be not only more sensitive than the known radio- and enzyme-immuno techniques, but renders it furthermore possible to demonstrate . , :

~3S~3 and to determine more than one immunological component in the same test medium simultaneously by utilizing sol particles of different chemical composition as labels.
The metal sols may be of metals or metal compounds, such as metal oxides, metal hydroxides and metal salts or of polymer nuclei coated with metals or metal compounds. As ex-amples, there may be named the metals platinum, gold, silver and copper, and the metal compounds, silver iodide, silver bro-mide, copper hydrous oxide, iron oxide, iron hydroxide or hy-drous oxide, aluminium hydroxide or hydrous oxide, chromiumhydroxide or hydrous oxide, vanadium oxide, arsenic sulphide, manganese hydroxide, lead sulphide, mercury sulphide, barium sulphate and titanium dioxide. In general all metals or metal compounds, which may be readily demonstrated by means of known techniques.
It is sometimes advantageous to use sols with dis-persed particles consisting of polymer nuclei, coated with the above mentioned metals or metal compounds. These particles have similar properties as the dispersed phase of pure metals or metal compound~, but size, density and metal content can be optimally combined.
Use is preferably made of metals or metal compounds which are not or in very small quantities present in the test medium, in particular of those metals or metal compounds which have a low detection limit in suitable analysis techniques.
The metal sol particles to be used as label may be prepared in a large number of ways which are in themselves known. For example, for the preparation of a gold sol reference is made to an article by G. Frens in Nature Physical Science 30 241, 20 (1973).
The metal ~ol particles carry a charge which confers a stabilizing effect by mutual repulsion. By addition of chief-ly strong electrolytes, the charge pattern is changed, as a result of which aggregation and flocculation occurs. This may be prevented by coating the particles with macromolecules possessing polar groups, such as proteins, polyethylene glycols, polymeric carbohydrates, polyvinyl alcohols and similar.
As protective proteins, it is possible to use anti-gens, antibodies and anti-antibodies, or immunochemically active frag~ents thereof, or haptens that have been coupled to immuno-chemically inert, protective macromolecules, which results di-rectly in immuno-components labelled with metal sol particles.
It is not necessary that immuno components are used exclusively for the coating of the metal sol particles, since though this does provide a stabilizing effect, the immunoche-mical reactivity may be less than expected, probably due to steric hindrance. It has therefore also proved advantageous to coat only partially with an immunocomponent, and to complete the coating with another protective, but immunochemically inert, material, such as inert proteins, for example albumin, a poly-ethylene glycol, or another polar macromolecule. As coating ma-terial, use may also be made of protein A or related proteins, which possess reactivity with respect to the Fc part of anti-bodies. After the coating of the metal sol particles with pro-tein A, a further coating may be brought about with a selected antibody.
Another possibility consists of first coating the metal sol particles with an inert hydrophilic macromolecule, e.g. a polymer or co-polymer, after which the immunological com-ponent is coupled to the coating material by adsorption or by covalent binding.

The globules obtained after coating may contain a ~135~?3 single metal sol particle, but it is also possible that the polymer encloses more than one metal sol particle.
The coating of the metal sol particles by the inert polymer may take place in two ways, either by bringing the metal sol into contact with the polymer or by introducing the metal sol into an environment containing a monomer, or various mono-mers, and causing these to polymerize or co-polymerize respect-ively in situ. The polymerization can be initiated under the influence of radiation, or by the addition of initiators, such as a persulphate.
- The coating of a metal sol particle by polymerization of the monomeric medium in which the particle is located, under the influence of an inorganic initiator such as a persulfate, meets with practical difficulties, since the sol flocculates on addition of such an initiator. It has now been found that such a coating is however possible by first protecting the metal sol particles, then introducing the protected particles into the monomeric medium, and after that finally initiating the polymer-ization. me compounds mentioned above merit consideration as protective material.
The components labelled with metal sol particles are used as a reagent, generally in combination with other reagents for the demonstration and quantification of receptor proteins and haptens, antigens and antibodies in an aqueous test medium, for which all sorts of immunochemical techniques, in use in radio-immuno and enzyme-immuno tests, receive consideration.
me invention therefore also relates to test-kits for use in such immunochemical techniques, which contain as the most important component a metal-labelled immunocomponent, consisting of a metal sol, the particles of which have either been directly coated by the desired immunocomponent, or have 1135~3 been coated by an inert macromolecule, onto which the immuno-component has be-en coupled or adsorbed.
One of the usual immunochemical techniques is the competitive immunotest, which can be used for the demonstration and estimation of every immunocomponent. For the demonstration, for example, of a certain antigen this method consists of bring-ing a test sample, containing an unknown quantity of antigen, into contact with either a certain amount of the metal-labelled antigen concerned and an insolubilized antibody ayainst this antigen, or a certain amount of insolubilized antigen and a metal-labelled antibody against this antigen.
After an adequate reaction time, the nature and/or the amount of the metal is determined in the bound or free frac-tion, which gives a qualitative or quantitative indication res-pectively of the antigen to be determined. With due changes in the details, an analogous method applies to the determination of other immunocomponents.
The so-called Sandwich techniques are also much used.
These are also particularly suitable for the use of a metal-labelled component according to the invention. According tothese techniques, an immunological component, for example an antibody if an antigen has to be determined, is rendered insolu-ble by coupling to a solid carrier. This solid carrier is for example the interior surace of the reaction vessel in which the immunochernical reaction is performed. After an initial incuba-tion, optionally followed by a washing step, a second incuba-tion with a metal-labelled antibody takes place, after which the metal is determined in the bound or the free phase. It is ad-vantageous to determine the metal in the bound phase. In this 3~ case after the separation of phases, the bound label is prefer-ably disengage~ so that the metal can be determined in the ob-,, --~3--,~

S~

tained liquid.
Furthermore, a homogeneous agglutination can be used.If the test sample contains the immunochemical component to be determined, agglutination occurs with the labelled immunochemi-cal component, resulting in a change of optical properties. A
qualitative or semi-quantitative result can be obtained by ob-servation of the colour change. It is also possible to observe the coarse of the reaction with a spectrophotometer.
In addition to the above-noted techniques, there are numerous other immunochemical techniques in which the metal-labelled immunocomponents can be used as reagent. 'rhe present invention also makes it possible to demonstrate different hap-tens, antigens, antibodies or combinations thereaf at the same time in one test sample, by using as reagent for each of the com-ponents to be demonstrated an immunocomponent which has been labelled with a different metal sol particle.
me measurement of the physical properties and/or the concentration of the metal and/or the formed metal containing agglomerate in a certain phase of the reaction mixture may take place u~ing numerous techniques, which are in themselves known.
As examples of these techniques there may be cited the colorime-tric determination, in which use is made of the intense colour of some dispersions which furthermore change colour with physi-cochemical changes, the visual method, which is often already applicable to qualitative determinations in view of the above-noted fact that metal sols are coloured, the use of flame emission spectrophotometry or another plasma-emission spectro-photometric method which renders simultaneous determination possible, and the highly sensitive method of flame-less atomic absorption spectrophotometr~.
'rhe invention is also related to test ki-ts to be 11351~3 used for the determination of one or more components of the re-action between a specific binding protein and the corresponding bindable substance in an aqueous medium, containing:
a) a metal labelled component which has been obtained by coupling a component of said reaction to particles of an aqueous dis-persion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, which particles have a size of at least 5 nm;
b) other reagents.
Preferably the test kit contains a metal labelled com-ponent, consisting of a sol, having particles with a size varying from 10-100 nm, which are either directly coated by the compo-nent of said reaction or by an inert polymer, to which the de-sired component has been coupled.
The metal-labelled component of the test kit accord-ing to the invention can be a metal-labelled immunocomponent.
me metal-labelled component can be present as a dispersion, but it appeared to be surprisingly possible to obtain a stable freeze-dried product, that can be redispersed before use. ~he freeze-dried metal-labelled component can also contain the buffer substance, that is required for carrying out the reaction between the specific binding protein and the corresponding bind-able substance.
The invention is further illustrated by means of the following examples.
Example I - Colorimetric determination of human placental lacto-gen (HPL) with the aid of an antibody, labelled with gold par-ticles, from a rabbit anti-HPL serum.
1.1. Preparation of the qold sol 500 ml of a 0.10 g/l chloro-auric acid (HAUC14) so-lution in distilled water is heated to boiling point in a beaker ~13S~83 of 800 ml capacity. 3.5 ml of a 10 g/l solution of tri-sodium citrate in distilled water is introduced into the boiling solu-tion, after which the gold sol, which has become dark red after an initial blue colour, is boiled for a further 15 minutes. Af-ter cooling to room temperature, the red gold sol thus obtained is made up to a volume of 500 ml with distilled water in a volu-metric flask. The gold sol obtained in this way consists of gold particles with diameters between 45 and 70 nm, as verified by electron microscopy. A gold sol prepared in this way has a pH of 3.45 - 0.07 and a light-absorption maximum at 536 nm, While 536 nm 1.2. Preparation of rabbit anti-HPL sera Anti-HPL sera were prepared by injecting an HPL solu-tion into rabbits according to the following scheme:

Day Method of ~ g HPL Dissolved in with CFA
iniection NaCl 9 a/l 1intramuscular 100 0.5 ml 0.5 ml " 200 0.5 ml 0.5 ml 29 " 400 0.5 ml 0.5 ml 20 43intravenous 200 1.0 ml blood sample for determination of the titre of the anti-~erum in an EIA test.
me rabbits were bled out as soon as the titre of the antiserum in an EIA HPL test was greater than 1:5000. If this was not the case, the rabbits received an additional injec-tion of 200 ~g HPL in 1.0 ml 9 g/l NaCl (intravenous) and the titre of the antiserum was determined again 7 days after this injection. The antisera were stored at -25C or freeze-dried and then stored as a dry powder at -25C.
1.3. Preparation of the anti-HPL immune qlobulin solution from the rabbit anti-HPL serum.

.

~135~

For this purpose, 600 mg freeæe-dried rabbit anti-HPL serum is dissolved in 7.5 ml of an 9 g/l NaCl solution. 10 ml 180 g/l ~a2SO4 solution in distilled water is then added, followed by 1.35 g solid Na2S04. The turbid liquid obtained is allowed to stand in a centrifuge tube for 1 hour, after which the liquid is centrifuged at 25000 N/kg for 10 minutes. The supernatant is sucked of~ and the residue is redispersed in 20 ml of an 180 g/l Na2S04 solution in distilled water. This pro-cedure is repeated twice.
After the last centrifugation and removal of the supernatant by suction, the residue is dissolved in 20 ml of a 9 g/l solution of NaCl in distilled water. Thi5 solution is dia-lysed against 6 litres dialysis liquid consisting of a 0.3 g/l NaCl solution in distilled water, which has been adjusted to a pH of 7.0 with a solution of 0.2 mol K2CO3 in 1 litre distilled water. Dialysis is continued for 16 hours at 4C, after which the dialysed liquid is centrifuged at 160000 N/kg for 20 minutes.
The immunoglobulin solution is stored in 1 ml vials at a tempe-rature of -20C.
The immunoglobulin content is determined by measuring A1260 nm and A180 nm of a tenfold dilution of the immunoglobulin solution, using a spectrophotometer. Ihe immunoglobulin con-tent G in mg/ml can then be calculated using the formula G = 10 x [(1.45 x A280 nm)~(0-75 x A260 nm)]-1.4. Preparatlon of the qold particle - rabbit anti~HPL
_mrnunoqlobulin coniuqate.
500 ml of the gold sol prepared in the way described under 1.1. is adjusted to pH 7.0 by means of a solution of 0.2 mol K2C03 in 1 litre distilled water. 0.5 ml of the rabbit anti-HPL immunoglobulin solution, with a content of 125~ g immu-noylobulin pcr ml, is acldecl dropwise with vigorous stirring to 1~35183 25 ml of the neutralized gold sol. 0.5 ml of a 50 g/l solution of bovine serum albumin (BSA) in 5 mmol NaCl/litre is distilled water, which has been adjusted to a pH of 7.0 with a 0.2 mol K2CO3 solutlon in 1 litre water, is then added, also with stir-ring.
The ~old particle-rabbit anti-HPL immunoglobulin con-jugate obtained in this way is centrifuged at 25000 N/kg for 10 minutes, after which the supernatant liquid is sucked off. The red pellet, consisting of the conjugate, is taken up in such a volume (about 23 ml) of trometamol, 0.01 mol/litre adjusted to a pH of 7.4 with 0.01 mol/litre HCl in distilled water (0.01 mol/litre TRIS/HCl buffer, pH = 7.4), that the final A536Cmnm is 1.00.
1.5. Coatinq of Microelisa (R) plates with rabbit anti-HPL
immunoalobulins.
To this end a rabbit anti-HPL immunoglobulin solution is prepared with a content of 25~ g immunoglobulin per ml, in a solution of 0.04 mol Na2HPO4 per litre adjusted to a pH of 7.4 with a solution of 0.04 mol NaH2PO4 per litre, both in distilled water, to which 0.1 g/l Merthiolate has been added.
0.1 ml of the above-described immunoglobulin solution iR placed in each well of the Microelisa(R) plate, after which the plate is incubated for 16 hours at 0 - 4C. 0.1 ml 200 g/l BSA Rolution in a 0.04 mol/l phosphate buffer, pH 7.4, to which 0.1 g/l Merthiolate has been added, is then pipetted into each well, and the whole is incubated for a further 30 minutes at room temperature. The wells of the Microelisa( ) plates are now sucked empty and washed 3 times with distilled water, after which khey are kept at -~.0C until use.
1.6. Test Protocol for HPL estimation with qold particle rabbit anti-HPL immunoqlobulin coniu~ate.

!: 13 il351~3 1.6.a. Determination of a standard curve for HPL
A standard curve was constructed for HPL according to the protocol below.
1. Pipette 0.1 ml of the standard HPL solution into a well of a Microelisa( ) plate coated with rabbit anti-HPL immunoglobulin and incubate for 2 hours at room temperature.
2. Suck the well empty and wash it with 0.1 ml 0.01 mol/l Tris/
- HCl buffer, pH 7.4.
3. Pipette 0.1 ml gold particle rabbit anti-HPL immunoglobulin conjugate (A136Cm = 1.00) into the well and incubate overnight at room temperature.
4. Empty the well by suction and wash it with 0.3 ml 0.01 mol/l Tris/HCl/~aCl buffer, pH 7.4.
5. Pipette 0.1 ml 0.1 mol/1 HCl solution in water into the well and allow this to act for 30 minutes in the shaker.
6. Measure the light absorption at 536 nm with a small-volume spectrophotometer.
The results of the determination of a standard curve are given in the table below.
20 HPL concentration in the standard _53~, ^t t~L~5G
olution, na/ml the test 0 0.030 0.2 0.030 0.8 0.060 3.2 0.106 12.5 0.136 0.188 200 0.220 The solvent for the HPL standard solution is 0.04 mol/l phos-phate buffer + 1 g/l BSA + 9 g/l NaCl, pH 7.4.
1.6.b. Determination of HPL in the serum of pre~nant women.

The sera of pregnant women were diluted such that the HPL level ranged from 5 to 80 ng/ml.
'me diluent for the sera was 0.04 mol/l phosphate buffer, pH 7.4 ~ 1 g/l BSA + 9 g/l NaCl.
With the aid of the test protocol described under 1.6.a., the HPL concentrations of the diluted sera were deter-mined using the standard curve constructed. After correction for the dilution factor, the following results were obtained.
Serum HPL content, EIA test HPL content, MIA
A 4.5 + 0.5 ~g~ ml 4 - 1 ~g~ ml B 3.2 - 0.4 ~g/mll 3.5 - 0.8 ~g/ml C 0.7 + 0.1 ~g/ml 1 + 0.3 ~g/ml EXAMPLE II - Determination of HPL with the aid of gold-particle-labelled antibodies and atomic absorption spectrophotometry.
2.1. Pre~aration of reaqents and coated Microelisa plates The method of preparation of the gold particle rabbit anti-HPL immunoglobulin conjugate and the Microelisa(R) plates coated with rabbit anti-HPL immunoglobulin was the same as des-cribed in Example I.
2.2. Test protocol 2.2.a Determination of standard curve for HPL
In order to construct a standard curve for HPL, ~erial dilutions of HPL were made of consecutively 1, 10, 100 and 1000 ng/ml and a blank. me solvent for HPL was 0.04 mol/l phosphate buffer, pH 7.4, to which 1 g/l BSA and 9 g/l NaCl had been added.
1. Pipette 0.1 ml standard HPL solution into the well of the coated Microelisa plate and incubate for 2 hours at room tem-perature.
2. Suck the well empty and wash with 0.1 ml 0.02 mol/l Tris/HCl buffer, pH 7,~, .~! -15-1~3S1~33 3. Pipette 0.1 ml of the bold particle anti-HPL antibody conju-gate (A136Cmnm = 1.00) into the well and incubate this overnight (about 16~hours~.
4. Suck the well empty and wash it with 0.02 mol/l Tris buffer, pH 7.4.
5. Pipette 0.1 ml HCl, 0.1 mol/l, into the well and allow this to act with shaking on a shaking machine for 30 minutes.
6. ~ow measure the peak value of the light absorption at 242.8 nm in a flame atomic absorption spectrophotometer fitted with a small-volume injector.
A typical example of a standard curve obtained in this way is shown in the table below.
HPL concentration in Peak value of light absorption standard solution at 242.8 nm after termination of the test 0 ng/ml 0.020 1 ng/ml 0.040 10 ng/ml 0.160 100 ng/ml 0.200 201000 ng/ml 0.220 2.2.b. Determination of HPL in the serum of preqnant women.
The sera of pregnant women were diluted such that the HPL level lay in the range 5 - 80 ng/ml. The diluen-t for the sera was 0.04 mol/l phosphate buffer (pH = 7.4) + 1 g/1 BSA
+ 9 g/l NaCl. With the aid of the test protocol described under 2.2.a., the HPL concentration~ of the diluted sera were deter-mined using the standard curve constructed.
EXAMPLE III - Visual detection of hepatitis Bs antigen (HBsAg) by means of gold particle sheep anti-HBs immunoglobulin conju-gate.
3.1. Preparation of the qold sol ' -16-~13~ 3 See example 1.1.
3.2. Preparation of sheep anti-HBs sera Sheep were in~ected with purified HBsAg solution.
3.3. Preparation of the sheep anti-H~s immunoqlobulin solution 1.4 g solid Na2SO4 is added to 10 ml sheep anti-HBsAg serum. After all the sodium sulphate has dissolved, the turbid liquid is allowed to stand for 1 hour at room tempera-ture. ~he liquid is then centrifuged at 25000 N/kg for 10 mi-nutes. me supernatant is removed by suction and the residue is redispersed in 10 ml 140 g/l Na2SO4 solution in distilled water. This procedure is repeated twice.
After centrifuging for the last time and removing the supernatant by suction, the pellet is dissolved in 10 ml of 9 g/1 ~aC1 solution in distilled water. mis solution is dialysed against 6 litres of a 0.3 g/l NaCl solution in dis-tilled water, adjusted to a pH of 7.0 with a solution of 0.2 mol/l K2C03. Dialysis takes place for 16 hours at 4C, after which the dialysed liquid is centrifuged for 20 minutes at 160000 N~kg.
The immunoglobulin solution is stored in portions of 1 ml in vials at -20C. The immunoglobulin content is deter-mined by the A16oCmnm, A18Comnm method already described.
3.4. Pre~aration of the qold-particle sheep anti-HBs immuno-alobulin con1~qate.
The preparation of the conjugate is identical with the method of preparation described in example I point 4, with the exception that a diluted solution (also 125 ng immunoglo-bulin per ml) of the sheep anti-HBs immunoglobulin solution was used instead of the rabbit anti-HPL immunoglobulin solution.
3.5. Coatina of Microelisa( ) plates with sheeP anti-HBs mmunoalobulins : .. - .....

~35~

The coating of Microelisa( ) plates with sheep anti-HBs immunoglobulins is performed in the way described in example I point 5, whereby the sheep anti-HBs immunoglobulin solution was used instead of a rabbit anti-HPL immunoglobulin solution. Ten control wells were included in each plate. These wells were coated with an immunoglobulin solution from human serum which was negative in the following tests:
- Hepanosticon and Hepanostika - Monosticon - Rheumanosticon - Immunodiffusion against normal sheep serum - EIA for anti-HBs.
3.6. Test protocol for a visually readable test.
1. Pipette 0.1 ml of the sample into a well of the coated Micro-elisa plate and incubate for 2 hours at 37C.
2. Wash each well 3x with 0.3 ml 0.02 mol/l Tris/HCl buffer, pH 7.4.
3. Pipette 0.1 ml gold-particle sheep-anti-HBs conjugate 1A136m = 1.00) into the well and incubate overnight at room temperature.
~. Empty the well by suction and wash it 3x with 0.3 ml 0.01 mol/l Tris/HCl/NaCl buffer, pH 7.4.
5. Pipette 0.1 ml 0.1 mol/l HCl solution in distilled water into the well and allow this to act for 30 minutes, on a shaker.
6. A3~ess visually the colour of the liquid in the well and compare it with the control wells present.
Sera which gave a strong positive reaction in the Hepanostika test could generally still be distinguished from the controls in 8-fold dilution.
EXAMPLE IV - Determination of testosterone with the aid of a silver particle testosterone~ -succinyl-bovine serum albumin ~L~351~3 conjugate.
4.1._Preparation of the silver sol ~ .5 ml of a 10 g/l AgNO3 solution in distilled water is diluted with 486~5 ml distilled water and 5.0 ml of a 10 g/l solution of trisodium citrate.2H20 in distilled water is then added. 40.0 ml of a 10 g/l solution of hydrazine in distilled water is added to this solution at room temperature with vigorous stirring using a magnetic stirrer. A grey-yellow-green silver sol with a strong Tyndall scattering is formed within 60 seconds.
After 10-fold dilution with distilled water, the pH was ~.85 and the sol had a light absorption of A1416Cmnm = 0.83.
20 ml of the undiluted sol was centrifuged for 10 minutes at 25000 ~/kg. 15 ml of the supernatant was removed by suction and replaced by 15 ml of a 0.1 g/l trisodium citrate.
2H20 solution in distilled water (pH 6.88).
The washing process was repeated twice. After the final washing, the volume was made up to 20 ml with the 0.1 g/l sodium citrate solution.
After 4-fold dilution with distilled water, the sol 0 had the following properties: `
max = 416 nm 416 nm 1.12 pH = 7.0 4.~. Preparation of testosterone~ -hemisuccinate-BSA
40 mg testosterone-ll ~-hemisuccinate is dissolved in 2 ml dimethyl-formamide and the solution is cooled to -15C.
140 mg bovine serum albumin is dissolved in 3 ml distilled water, after which 1 drop 4N NaOH and 2 ml DMF are added, and the whole is cooled to -15C.
12.5 ~1 N-methylmorpholine and 12.5~11 isobutyl chloroformate are now added to the steroid solution. After 3 1135~33 minutes, the solution is added to the BSA solution. After stir-ring,for 1 hour at -15C and 3 hours at 0C, the solution is transferred to a dialysis bag and dialysed overnight against running tap water. The dialysate is passed through a Sephadex G25TM column, optionally after centrifugation, and the protein fraction is collected and freeze-dried.
4.3. Preparation of antisera for testosterone Rabbits were immunized by injection of 1.25 mg tes-tosterone-ll ~-hemisuccinyl-BSA, dissolved in 2.5 ml physio-logical saline, and 2.5 ml complete Freunds adjuvant (1 ml i.m. 3x, interval 1 week). They were then given an i.v. in-jection of 1 ml of a solution of 1.25 mg testosterone-ll~ -hemi-~uccinyl-BSA in 5 ml physiological saline.
This injection scheme was repeated until the titre of the antiserum was sufficiently high. The rabbits were then bled out, and the sera were stored at -20C until use.
4.4. Preparation of polystyrene tubes coated with rabbit immuno-~lobulin aqainst testosterone A rabbit anti-testosterone immunoglobulin solution is made by salting out with 180 g/l Na2S04 as described in example I point 2.
The dialysed immunoglobulin solution is diluted (to a concentration of 1~ g immunoglobulin/ml) with a buffer con-sisting of 0.1 mol/litre NaH2P04.H20, 60 g/l sucrose, adjusted to pH 7.4 with 4 mol/l NaOH. 1 ml of the immunoglobulin solu-tion i9 pipetted into each 3 ml polystyrene tube, and incubated overnight at room temperature. The tubes are then emptied by suction and filled with 1 ml 10 g/l BSA solution in the above-noted buffer. After two hours, the tubes are emptied by suc-tion and washed 3x with 3 ml distilled water. The tubes are dried completely by suction and are further drled over silica ~L1351S~3 gel overnight. They are then packed in aluminum foil in sets of 25 with a bag of silica gel and stored at 4C.
4.5. Preparation of silver particle-testosterone-ll ~-hemi-succinyl-BSA conjuqate 20 ml of the silver sol, prepared as described in 4.1., was diluted with 80 ml 0.3 g/l NaCl and the pH was adjusted to 7.0 with 0.01 mol/litre NaOH solution in distilled water. A421C nm = 1.08.
3 ml of a solution of testosterone-ll ~-hemisuccinyl-10 BSA, 175 ~ g/ml in 0.3 g/l NaCl adjusted to pH 7.0 with 0.01 mol/l NaOH, is then added dropwise to 15 ml of this sol with vigorous stirring by a magnetic stirrer.
The whole is incubated for about 10 minutes, afterwhich 2 ml 10 g/l Carbowax 20M solution in 0.3 g/l NaCl, adjusted to pH 7.0 with 0.01 mol/l NaOH, is added. The crude conjugate is subsequently washed by centrifuging 10 ml at 25000 N/kg for 20 minutes. 9 ml supernatant is now removed by suction and re-placed by 9 ml washing liquid consisting of 1 g/l Carbowax 20M
solution in 0.3 g/l ~aCl, adjusted to pH 7.0 with 0.01 mol/litre NaOH dissolved in distilled water. After washing 3 times, the conjugate is again centrifuged after which the supernatant liquid is removed by suction. me residue is redispersed in 0.02 mol/litre phosphate buffer, pH 7.4. me conjugate solution now has a pH of 7.4 and A421C nm = 1.08. The washed conjugates are stored at 4C until use.
4.6. Test protocol for the determination of testosterone with the silver particle testosterone-ll ~-hemisuccinyl-BSA coniuqate 1. Pipette a 1 ml sample into a polystyrene tube coated with rabbit anti-testosterone immunoglobulin and incubate for 2 hours at room temperature.
2. Empty the tube by suction and wash 3x with 2 ml 0.02 * - Trademark ~ l 1135~83 mol/litre phosphate buffer, pH 7Ø
3. Pipette 1 ml of the silver particle testosterone~
hemisuccinyl-BSA conju~ate, A42Clmnm = 1.08, into the tube and incubate for 16 hours.
4. Now suck the tube empty and wash with 2 ml 0.02 mol/litre phosphate buffer, p~ 7Ø
5. Pipette 1 ml 0.1 mol/litre HCl, solution in distilled water, into the tubes and allow this to act for 30 minutes.
6. Measure the liquid in the tube A121Cm 4.7. Results Ihe test media were colourimetrically determined with the aid of a standard curve, whereby amounts of testosterone of the magnitude of 0.5 nc3/ml and greater could be determined.
EX~PLE V - Determination of the titre of human anti-Rubella sera 5.1. Preparation of the Rubella anti~en 200 ml of a host cell suspension (BHK 21C3 from the Rijks Instituut voor Volksgezondheid, RIV) in culture medium (concentration 10 live cells per ml) is introduced into a roller bottle (surface 490 CM ). The cell culture is lcept for 16 to 20 hours at 37C. The culture medium is tnen removed and the cell layer is washed twice with 20 ml phosphate-buffered saline solution (PBS). 10 ml ~irus suspension (virus type ~33 RI~) is th~n diluted 1:100 with PBS and introduced into the bottle, after which the whole i~ :incubated at 37C for about 2 1/2 hours.
100 ml maintenance medium is now added and the cul-ture is then kept at 37C. After a period of at least 64 hours, but not exceeding 136 hours, depending on the assessment of the cytopathic effecl, the incubatecl mono]ayer of infected cells is harbe.sted. The mairltenarlce mediurrl is remove(l, and the mono-, . ...

11351~33 layer of cells is washed once with 20 ml PBS. The cells are loosened from the wall by means of sterile glass beads, taken up in 90 ml PBS and frozen at -20C.
After thawing, 10 ml glycine solution (1 mol/l), the pH being adjusted to 9.0 with solid NaOH, is added to 90 ml cell suspension, and the whole is thoroughly mixed for 6 hours at 37C. The cell suspension is now ultrascnicated for 30 minutes, with cooling in ice, and subsequently centrifuged at 30000 ~kg for 30 minutes at 4C. The supernatant containing the Rubella virus is collected and inactivated by consecutive addition of:
1:100 (v/v)NaOH (1 mol/litre) solution in distilled water 1:100 (v/v) freshly prepared 10%~ -propiolactone solution in distilled water, The liquid is allowed to stand for 48 hours at 4C, after which it is centrifuged for 30 minutes at 30000 N~kg and 4C.
me supernatant is the liquid containing the Rubella virus, which can if necessary be stored at -20C until use.
5.2. Coatinq of Microelisa( ) plates with Rubella antiaens.
The Rubella antigen solution, prepared as described in 5.1., is diluted 1:100 with a 0.05 mol/litre carbonate buffer, pH 9.6. 100 ~1 of this liquid Rubella antigen solution is pipetted into each well of the Microelisa plate and the whole is subsequently incubated for 16 hours at 4C. The well of the Microelisa(R) plate are now emptied by suction and washed 3 times with 300 ~1 0.05 mol/l phosphate buffer, pH 7.4, to which 9 g/l NaC1 and 0.5 g/l Tween 20 have been added.
5.3. Preparation of sheet anti-human immuno~lobulin solution Normal human serum is salted out with 140 g/1 Na2SO4, which i5 added as a solid in small portions. After standing for 1 hour at room temperature, the turbid liquid is centri-1~351~3 fuged at 25000 N~kg for 10 minutes. The supernatant is removed by suction, after which the residue is washed with a 140 g/l Na2S04 solution in distilled water. After centrifuging and removal of the supernatant by suction, the residue is dissolved in 9 g/l ~aCl, after which the immunoglo~ulin solution is dia-lysed for 48 hours against 9 g/l NaCl at 4C. The immunoglo-bulin content is then determined by the A126ocml A128Com method.
Sheep were immunized with a diluted solution of this human immunoglobulin solution according to the following scheme:
day 1 0.5 mg human immunoglobulin dissolved in 0.5 ml physio-logical saline, to which 0.5 ml complete Freunds adju-vant has been added.
Injection: intramuscular.
day 14 1.0 mg human immunoglobulin dissolved in 0.5 ml physio-lGgical saline, to which 0.5 ml incomplete Freunds ad-juvant has been added.
Injection: intramuscular.
day 28 2.0 mg human immunoglobulin dissolved in 0.5 ml physio-logical saline, to which incomplete Freunds adjuvant has been added.
Injection: intramuscular.
day 42 1.0 mg human immunoglobulin dissolved in 1.0 ml physio-logical saline.
Injection: intravenous.
day 56 Sampling of blood.
The immunoglobulin fractions were obtained from the sheep anti-human immunoglobulin sera by salting out according to the above-described 140 g/l Na2S04 method. After washing for the third time, the residue was dissolved in 9 g/l NaCl, after which the immunoglobulin solution was dialysed against a 0.3 " -24-1135~83 g/l NaCl solution in distilled water, adjusted to pH 7.0 with 0.2 mol/l K2C03 dissolved in distilled water.
After centrifuging this dialysed sheep antihuman immunoglobulin solution at 160000 N~kg for 15 minutes, the immunoglobulin content was determined by the A16oCm , A18Com method.
5.4. Preparation of the qold-particle sheep anti-human immunoqlobulin conju~ate The gold sol was ~repared by the method described in 1.1 and the conjugate was prepared in a way analogous to the method described in l.r. whereby in this case the sheep immuno-globulin solution prepared in 5.3. was used, with an immuno-globulin content of 125~ g per ml.
5.5. Test ~rotocol ~ he sample of human sera is diluted 1:25 with 0.2 mol/l Trometamol/HCl/NaCl buffer, pH 7.4, to which 0.5 g/l Tween 20 has been added.
1. 100~ 1 of diluted human serum is pipetted into each well and the whole is incubated for 30 minutes at room temperature.
2. me well is emptied by suction and washed three times with 300~ 1 0.2 mol/l Trometamol/HCl/NaCl buffer, pH 7.4, to which 0.5 g/l Tween 20 has been added.
3. 100~ 1 gold particle sheep anti-human immunoglobulin conju-gate (A536 nm = 1.00) is now pipetted into the well and the whole i4 incubated for 16 hours at room temperature.
4. The well is emptied by suction and washed 3 times with 300,~1 0.01 mol/l Trometamol/HCl/NaCl buffer, pH 7.4, to which 0.5 g/l Tween 20 has been added.
5. Pipette 100~ 1 0.1 mol/l HCl dissolved in distilled water into the well and allow this to act for 30 minutes while shaking.

6. ~fter this, measure the light absorption at 536 nm, using ~1135i83 a small volume spectrophotometer.
5.6. Results An A136Cmnm of about 0.230 was measured for sera with an HAI titre of 512, while a reasonable linear correlation was further found between the HAI titres of the human sera inves-tigated and the A136C nm ~ values obtained in the above-mentioned test.
EXAMPLE VI - Determination of HCG with the aid of an iron oxide -anti-~CG conjugate. ~
6.1. Preparation of the iron oxide sol A solution consisting of 9 mmol/l FeC13 and 1 mmol/l HCl is heated to a temperature of 95C during 65 hours. The initially slightly yellow solution discolours to orange-red due to the formation of iron oxide sol particles. The iron oxide sol obtained in this way consists of cubic iron oxide particles with an edge between ~0 and 80 nm as verified by electron microscopy.
A local light-absorption maximum is found at 370 nm. A sol with aniron oxide content of 0.45 mmol/l exhibits an A137comnm =
1.0 and a pH of 2.7 just after the preparation.
6 2 PreParation of the iron oxide anti-HCG coniuaate Rabbit anti-HCG sera were prepared according to a method analogous to that described for anti HPL sera in example 1.2.
The immunoglobulin fraction hereof was obtained by adding Na2S04, separating the residue, redispersing the latter in a 180 g/l Na2S04 solution and dialysing this dispersion against a solution containing 5 mmol/l NaCl. The immunoglobulin content was determined as described in Example l.3.
The iron oxide sol of 5.1 was diluted, resulting in 30 an iron oxide content o~ 0.4S mmol/l. To 25 ml hereof, 0.5 ml ylutaraldehyde 250 g/l was added and the mixture was incubated ~35~3 during 30 minutes at room temperature and pH 2.8. Subsequent-ly, 0.63 ml rabbit anti-HCG immunoglobulin solution, containing 640 g/ml immunoglobulin, was added.
After an incubation of 1 hour at room temperature and pH 2.7 the pH of the mixture was adjusted to 7.0 with a NaOH solution and the incubation of the mixture was continued overnight at 0-4C.
Before use, the conjugates were washed by centrifug-ing, sucking off the supernatant and resuspending in a buffer 10 consisting of 0.1 mol/l 'rris/NaCl/HCl ~pH 7.4), 1 g/l BS~ and 0.2 g/l Carbowax 20M. Finally, the volume of the sol was ad-justed, so that A1370Cmnm - 1Ø
6.3. Coatinq of Microelisa(R) plates with rabbit anti-HCG
immunoalobulins Microelisa(R) plates were coated with rabbit anti-HCG
immunoglobulin as described for coating with anti-HPL immuno-globulins in example 1.5.
6.4. Test ~rotocol for NCG determination with iron oxide anti-HCG coniuqates A dose response curve was made for HCG, that is solved in a mixture of 0.04 mol/l phosphate buffer, 1 g/l BSA
and 9 g/l NaCl (pH - 7.4), according to the following test protocol.
1. Pipette 0.1 ml of the standard HCG solution into a well of a Microelisa( ) plate, coated with anti-HCG and incubate for 2.5 hours at 37C.
2. Suck the well empty.
3. Pipette 0.1 ml iron oxide anti-HCG (A370cmnm ~ 1.0) into the well and incubate during the night at 37C.
4. Empty the well by suction and wash it 8 times with 0.3 ml of a solution cDtaining 0.1 mol/l l'ris/HCl/~aCl buffer (pH - 7.4) .~.

113~ ?3 and 0.5 g/l Tween 20.
5. Pipette 0.1 ml of a solution containing 0.1 rnol/l NaOH and allow this to act for 15 minutes.
6. Measure the light absorption at 360 nm with a small volume spectrophotometer.
The results of a dose response curve are given in the table below.
HCG concentration in the standard Al cm solution, in mlU/ml -102000 0.367 1000 0.429 500 0.414 250 0.
125 0.275 63 0.205 31 0.179 16 0.172 8 0.154 4 0.142 20 0 0.096 6.5. Determination of HCG in the urine of preqnant women The urines of pregnant women were diluted such that the HCG level lay in the range 1-500 mIU ~ICG/ml. With the aid of the test protocol of 5.4. the HCG concentration of the di-luted samples were determined u~ing the standard curve construct-ed.
EXAMPLE VII - Determination of HCG with the aid of gold particle anti-HCG conjugate in an agglutination test.
7.1. Preparation of reaqents A gold sol is prepared according to the method des-cribed in 1.1. and rabbit anti-HCG sera and immunoglobulin 1~351~3 fractions hereof as described in 5.2.
A gold particle anti-HCG conjugate is prepared with the gold sol and the rabbit anti-HCG solutions according to the method described in 1.4.
7.2. Test ~rotocol 1. Pipette 1 ml of the gold particle anti-HCG conjugate (A540Cm m = 1.50) into a test tube of approximately 3 ml.
2. Pipette herein 0.1 ml of the urine to be tested and mix.
3. Judge the colour of the conjugate after an incubation of 1 hour at room temperature:
- a colour change from red to colourless indicates that the sample is strongly positive - a colour change from red to purple indicates that the sample is positive and contains 1 IU HCG/ml or more - if the colour does not change the sample is negative, i.e. it contains 0.4 IU HCG/ml or less.
7.3. Results With the aid of the test protocol of 7.2. it is pos-sible to diagnose pregnancy on the 33-35th day after the last menstruation.
EXAMPLE VIII - Competitive Receptor assay for HCG
8.1. Preparation of purified HCG receptor protein from bovine corPora lutea (BCL) HCG receptor protein from BCL was prepared by the method described in detail by Khan and Saxena in Enzyme Labelled Irnmunoassay of Hormones and Drugs ed. S.B. Pal, Publ.
Walter de Gruyter Berlin New York 1978. Fresh BCL tissue was pulverized, homogenized, filtered, further homogenized and centrifuged at 6500 N~kg. The supernate was centrifuged at 30 130,000 N/kg, the obtained pellct hornogenized and centrifuged in a zonal rotor with a sucrose gradient and elllted. q~he Ereeze ~135~183 dried fractions containing the HCG receptor membranes were re-dissolved and after centrifugation Mannitol was added to the clear supernate, whereafter the pH was adjusted to 7Ø The ob-tained dispersion was purified by affinity chromatograph on CNBr-activated sepharose 4B coupled with Human LH. After elution of the bound receptor, the pH was immediately adjusted to 7 and Triton X-100 was removed by adsorption on Bio-beads. The obtain-ed dispersion of HCG receptor protein was thoroughly dialyzed against PBS, pH 7.0 and stored at 4C.
8.2. Coatinq of Polvstyrene micro titration plates with HCG
receptor protein To this end a HCG receptor protein receptor solution is prepared with a content of 25 ~g protein/ml by diluting the HCG receptor protein in PBS with a solution of 0.04 mol/l ~a2HPO4, adjusted to a pH of 7.4 with a solution of 0.04 mol/l NaH2PO4 to which 0.1 g/l Merthiolate is added. Micro titration plates were coated with this HCG receptor solution according to the protocol described in 1.5.
8.3. Preparation of a qold dispersion A gold dispersion consisting of particles having a diameter between 6 and 15 nm was prepared by adding 14 ml of a solution containing lO g/l sodium citrate 2H2O to a boiling solution containing lO0 mg/l chloro-auric acid (HAUCl4), and the mixture is kept boiling for 15 minutes. The obtained orange red gold dispersion is cooled down to room temperature and re-adjusted to a volume of 500 ml in a volumetric flask. The gold dispersion had a light absorption maximum at 523 nm and A52C3mnm = 1Ø
8.4. Preparation of a ~old Particle HCG coniuqate A solution containing 5 mg purified HCG/ml in PBS

(p~ = 7.0) was thorouyhly dialyzed against a solution contain-~13S1~3 ing 5 mol/l NaCl, adjusted to a pH of 4.5 by means of HCl.
1 ml of the dialyzed HCG solution was added to 500 ml of the gold dispersion and stirred for 10 minutes at room temperature.
10 ml of a solution containing 10 g Carbowax 20 M/l was added to the fresh conjugate and incubated for another 10 minutes. There-after the pH was adjusted to 7.4 by means of a K2C03 solution.
The conjugate was stored at 4C. Just before use 1 ml of a 1 mol/l TRIS/HCl/~aCl buffer (pH - 7.4) containing 1 g/l BSA
was added to 10 ml of the stored conjugate dispersion.
8.5. Test protocol for a competitive HCG assay 100 ~1 of a standard HCG solution (or the sample) was added to a well of micro titration plates coated with HCG
receptor protein and incubated for one hour at room temperature.
Thereafter 100 ~1 of the buffered gold particle HCG conjugate was added and incubated for four hours at room te~perature. The well was emptied and washed with 0.3 ml 0.01 mol/l TRIS/HCl/~aCl buffer pH = 7.4.
Finally 0.1 ml 0.1 mol/l NaOH solution in water was added and incubated for 10 minutes. The light absorption of the fluid in a well was measured at 536 nm using a small volume ~pectrophotometer.
8.6. Result A dose-response curve for free HCG was obtained in a HCG concentration range between O and 1000 mIU/ml having a mid-point near 100 mIU }ICG/ml. q'he detection limit was about 10 mIU HCG/ml. The IICG concentration measured in samples was usually higher than determined with an EIA.
EXAMPLE ~X - Sandwich assay for HCG using an insolubilized HCG
receptor and a gold particle-anti HCG conjugate For this assay microtitration plates were coated with HCG receptor protein as describcd in Example ~.2. A yold par-~1351~3 ticle-anti HCG conjugate was prepared as described in Example 1.4. using rabbit anti-HCG instead of rabbit anti-HPL.
9.1. Test Protocol 0.1 ml of a standard solution HCG in 0.1 mol/l TRIS/HCl/NaCl buffer pH = 7.4 containing 1 g/l BSA (or sample) is pipetted into a well of the microtitration plate coated with HCG receptor protein and incubated for 1 hour at room temperature.
men the wells are emptied and 0.1 ml of the gold particle anti HCG conjugate is pipetted into each well and incubated over-night at room temperature. The wells are emptied and washed 6times with 0.3 ml 0.01 mol/1 TRIS/HCl/NaCl buffer pH = 7.4.
0.1 ml and 0.1 mol/l NaOH is pipetted into each well and incubated for 15 minutes. me light absorption at 536 nm of the content of the wells is measured using a small volume spectrophotometer.
9 2 Test results Dose response curves were obtained for HCG concen-tration between 0 and 1000 mIU/ml. The detection limit was about 5 mIU/ml. HCG concentrations measured in samples were about the same as measured with EIA.

....

Claims (83)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A method for the immunochemical determination of a first component of an immunological reaction system in an aqueous medium, comprising:
a) bringing a sample into contact with 1) a known amount of a reagent selected from the group consisting of metal sol particles which have an immunological component coupled to their surfaces, metal sol particles which have coupled to their surfaces (i) an immunological component, and (ii) a macromolecule which is immunologically inert, and metal sol particles coated with an immunologically inert hydrophilic polymer or copolymer, the surface of each coated particle having coupled to it an immunological component wherein the immuno-logical component of said reagent is similar to said first component and 2) a known amount of an insolubilized second component of said system-capable of reacting immunologically with said first component and said reagent, b) allowing the immunological reaction to take place, whereby a fraction bound to said insolubilized component and a fraction which is free from said insolubilized component are produced, c) and determining the amount of the metal of the metal sol particles in one of said fractions, which is a measure of the amount of said first component in said sample.
2. A method for the immunochemical determination of a first component of an immunological reaction system in an aqueous medium, comprising:
a) bringing a sample into contact with 1) a known amount of a reagent selected from the group consisting of metal sol particles which have an immunological component coupled to their surfaces, metal sol particles which have coupled to their surfaces (i) an immunological component and (ii) a macro-molecule which is immunologically inert, and metal sol particles coated with an immunologically inert hydrophilic polymer or copolymer, the surface of each coated particle having coupled to it an immunological component, wherein the immunological component of said reagent is a second component of said system capable of reacting immunologically with said first component and 2) a known amount of an insolubilized amount of an immuno-logical component which is similar to said first component and capable of reacting with said reagent, b) allowing the immunological reaction to take place whereby a fraction bound to said insolubilized component and a fraction which is free from said insolubilized component are produced, c) and determining the amount of metal of the metal sol particles in one of said fractions, which is a measure of the amount of said first component in said sample.
3. A method for the immunochemical determination of a first component of an immunological reaction system in an aqueous medium, comprising:
a) binding an amount of a second component of said system capable of reacting immunologically with said first component to the surface of a water-insoluble, water insuspens-ible, solid carrier, b) contacting said bound second component with a sample, c) allowing the immunological reaction to take place, d) contacting said bound second component with a known amount of a reagent selected from the group consisting of metal sol particles which have an immunological component coupled to their surfaces, metal sol particles which have coupled to their surfaces (i) an immunological component, and (ii) a macromolecule which is immunologically inert, and metal sol particles coated with an immunologically inert hydrophilic polymer or copolymer, the surface of each coated particle having coupled to it an immunological component, wherein the immuno-logical component of said reagent is capable of reacting with said first component, to bind said reagent to that part of said bound second component which has undergone the reaction in step (c), e) and determining the amount of the metal of the metal sol particles in the free reagent or the bound reagent, which is a measure of the amount of said first component in said sample.
4. A method for the immunochemical determination of human placental lactogen (HPL), comprising:
a) binding a known amount of rabbit anti-HPL
immunoglobulin to the surface of a water-insoluble, water-insuspensible, solid carrier, b) contacting said bound immunoglobulin with a sample solution, c) allowing the immunological reaction between the bound immunoglobulin and any HPL in the sample solution to take place, d) washing the solid carrier, e) contacting said bound immunoglobulin with a known amount of a reagent, said reagent consisting essentially of gold sol particles, said particles having rabbit anti-HPL
immunoglobulin coupled to their surfaces, to bind said reagent to that part of said bound immunoglobulin which has undergone the reaction in step (c), f) and determining the amount of gold in the free reagent or the bound reagent, which is a measure of the amount of HPL in said sample solution.
5. A method for the immunochemical determination of hepatitis Bs antigen (HBsAg), comprising:
a) binding a known amount of sheep anti-HBsAg immunoglobulin to the surface of a water-insoluble, water-insuspensible, solid carrier, b) contacting said bound immunoglobulin with a sample solution, c) allowing the immunological reaction between the bound immunoglobulin and any HBsAg in the sample solution to take place, d) washing the solid carrier, e) contacting said bound immunoglobulin with a known amount of a reagent, said reagent consisting essentially of gold sol particles, said particles having anti-HBsAg immunoglobulin coupled to their surfaces, to bind said reagent to that part of said bound immunoglobulin which has undergone the reaction in step (c), f) and determining the amount of gold in the free reagent or the bound reagent, which is a measure of the amount of HBsAg.
6. A method for the immunochemical determination of testosterone, comprising:
a) binding a known amount of rabbit anti-testosterone immunoglobulin to the surface of a water-insoluble, water-insuspensible, solid carrier, b) contacting said bound immunoglobulin with a sample solution, c) allowing the immunological reaction between the bound immunoglobulin and any testosterone in the sample solu-tion to take place, d) washing the solid carrier, e) after said reaction, contacting said bound immunoglobulin with a known amount of a reagent, said reagent consisting essentially of silver sol particles, said particles having testosterone-ll.alpha.-hemisuccinyl-bovine serum albumin coupled to their surfaces to form a silver particle-testo-sterone-ll.alpha.-hemisuccinyl-bovine serum albumin conjugate, said contacting of said reagent resulting in the binding of said reagent to that part of said bound immunoglobulin which has undergone the reaction in step (c), f) and determining the amount of silver in the free reagent or the bound reagent, which is a measure of the amount of testosterone.
7. A method for the immunochemical determination of the titer of human anti-Rubella sera, comprising:
a) binding a known amount of Rubella antigen to the surface of a water-insoluble, water-insuspensible, solid carrier, b) contacting said bound antigen with a human serum sample, c) allowing the immunological reaction between the bound antigen and the serum to take place, d) washing the solid carrier, e) contacting said bound antigen with a known amount of a reagent, said reagent consisting essentially of gold sol particles, said particles having sheep anti-human immuno-globulin coupled to their surfaces to form a gold particle sheep antihuman immunoglobulin conjugate, said contacting of said reagent resulting in the binding of said reagent to that part of said bound antigen which has undergone the reaction in step (c), f) and determining the amount of gold in the free reagent or the bound reagent, which is a measure of the titer of the human anti-Rubella serum sample.
8. A method for the immunochemical determination of HCG, comprising:
a) binding a known amount of rabbit anti-HCG
immunoglobulin to the surface of a water-insoluble, water-insuspensible, solid carrier, b) contacting said bound immunoglobulin with a sample solution, c) allowing the immunological reaction between the bound immunoglobulin and any HCG in the sample solution to take place, d) washing the solid carrier, e) contacting said bound immunoglobulin with a known amount of reagent, said reagent consisting essentially of iron oxide sol particles, said particles having anti-HCG immuno-globulin coupled to their surfaces, to bind said reagent to that part of said bound immunoglobulin which has undergone the reaction in step (c), f) and determining the amount of iron oxide in the free reagent or the bound reagent which is a measure of the amount of HCG in the sample solution.
9. A method for the immunochemical determination of HCG, comprising:
a) binding a known amount of rabbit anti-HCG immuno-globulin to the surface of a water-insoluble, water insuspens-ible, solid carrier, b) contacting said bound immunoglobulin with a sample solution, c) allowing the immunological reaction between the bound immunoglobulin and any HCG in the sample solution to take place, d) washing the solid carrier, e) contacting said bound immunoglobulin with a known amount of reagent, said reagent consisting essentially of gold sol particles, said particles having anti-HCG immunoglobulin coupled to their surfaces, to bind said reagent to that part of said bound immunoglobulin which has undergone the reaction in step (c), f) and determining the amount of gold in the free reagent or the bound reagent which is a measure of the amount of HCG in the sample solution.
10. A method for the immunochemical determination of HCG, comprising a) binding a known amount of a HCG receptor protein to the surface of a water insoluble, water insuspensible, solid carrier, b) contacting said bound HCG receptor protein with a sample solution, c) allowing the immunological reaction between the bound HCG receptor protein and any HCG in the sample solution to take place.
d) washing the solid carrier, e) contacting the bound HCG receptor protein with a known amount of a reagent, said reagent consisting essentially of gold sol particles, said particles having HCG conjugate coupled to their surfaces, to bind said reagent to that part of said bound receptor protein which has undergone the reaction in step (c), f) and determining the amount of gold in the free reagent or the bound reagent which is a measure of the amount of HCG in the solution.
11. Process for the detection and/or determination of one or more components of the reaction between a specific binding protein and the corresponding bindable substance in an aqueous test sample, whilst applying the known binding af-finity of such components for one another, which comprises providing one or more labelled components obtained by coupling directly or indirectly the desired component of said reaction to particles of an aqueous dispersion of a metal, metal com-pound or polymer nuclei coated with a metal or metal compound, having a particle size of at least 5 nm, contacting said aqueous test sample with said one or more labelled components, whereby during the reaction or after an adequate reaction time, the physical properties and/or the amount of the metal and/or the formed metal containing agglomerate is/are deter-mined in the test sample or in a derived fraction thereof, which determination provides a qualitative and/or quantitative indication of the component or components to be detected and/or determined.
12. Process according to claim 11, whereby the component or components of the reaction between a specific binding protein and the corresponding bindable substance are immuno-chemical components, which comprises providing one or more labelled components obtained by coupling directly or indirectly the desired immuno chemical component to particles or an aqueous dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, having a particle size of at least 5 nm, contacting said aqueous test sample with said one or more labelled components, whereby after an adequate reaction time, the physical properties and/or the amount of the metal and/or the formed metal contain-ing agglomerate is determined in the test sample or in a derived fraction thereof, which determina-tion provides a qualitative and/or quantitative indication of the immunological component or components to be detected and/or determined.
13. Process according to claims 11 or 12, wherein said detection and/or determination is carried out after separation of the bound and free labelled components.
14. Process according to claims 11 and 17, characterized in that one or more labelled components are used, obtained by coupling directly or indirectly the desired reactant to par-ticles of a sol, having a particle size varying from 10 to 100 nm.
15. Process according to claims 11 and 12, characterized in that the labelled component is obtained by adding to a sol of a metal, a metal compound or polymer nuclei coated with a metal or metal compound, a certain amount of the immunochemical component to be labelled, which latter completely or partially coats the sol particles, after which further coating may be carried out with an immunochemically inert polar macromolecule.
16. Process according to claims 11 and 12, characterized in that the labelled component is obtained by adding to a sol of a metal, a metal compound or polymer nuclei coated with a metal or a metal compound, one or more immunochemically inert hydrophilic macromolecules, which coat the sol particles, after which the immunochemical component is coupled to the coating material.
17. Process according to claim 11, characterized in that the labelled component is obtained by introducing a metal sol into an environment of monomers, causing these latter to polymerize, or co-polymerize respectively, in situ, so that coating of the sol particles results, and subsequently coupling the immunochemical component to the polymeric material.
18. Process according to claim 17, characterized in that the sol particles are first protected by a hydrophilic macro-molecule, after which (co)-polymerization occurs under the influence of an inorganic initiator.
19. Process according to claims 11-12, characterized by the use of particles of a sol of gold, silver or platinum or compounds of these metals or iron or copper compounds.
20. Process according to claims 11-12, characterized in that, after separation of the bound and the free labelled components, the physical properties and/or the amount of the metal is determined in the fraction containing the bound labelled component.
21. Process according to claims 11-12, characterized in that the immunochemical component or components to be deter-mined is/are allowed to react with one or more insolubilized immunochemical component, before the labelled component or components is/are added.
22. Process according to claims 11-12, characterized in that the bound labelled component or components is/are dis-engaged after separation of the free labelled component or components and the amount of the metal or metals is/are de-termined in the obtained liquid fraction.
23. Process according to claims 11-12, characterized in that two or more immunochemical components are determined in one test sample by use of two or more different labelled com-ponents.
24. Process according to claims 11-12, characterized in that the occurrance of a change in colour or colour intensity of the reaction mixture is observed or measured, which change is a qualitative or quantitative indication of the immuno-chemical component to be determined.
25. Test kit, to be used for the determination of one or more components of the reaction between a specific binding protein and the corresponding bindable substance in an aqueous medium, containing:
a) a metal-labelled component which has been obtained by coupling a component of said reaction to particles of an aqueous dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, which particles have a size of at least 5 nm, b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of (aa) a ligand capable of binding with the metal-labelled component (a);
(bb) a ligand capable of binding with a binding partner of the metal-labelled component (a);
(cc) a ligand capable of binding with at least one of the component(s) to be determined; and (dd) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined .
26. Test kit according to claim 25, of which the aqueous dispersion is a sol, having particles with a size varying from 10-100 nm, which are either directly coated by the component of said reaction or by an inert polymer, to which the desired component has been coupled.
27. Test kit according to claims 25 and 26, of which the labelled component is an immuno component.
28. Test kit according to claim 25, of which the labelled component is freeze-dried.
29. Test kit according to claim 25, of which the freeze-dried reagent contains also a buffer substance.
30. The process for the detection and/or determination of one or more components of the reaction between a specific binding protein and the corresponding bindable substance in an aqueous test sample, by applying the known binding affinity of such components for one another, comprising:
(a) employing one or more labelled components, obtained by coupling directly or indirectly the desired component of said reaction to particles of an aqueous sol dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, having a particle size of at least 5 nm, and (b) detecting and/or determining during the reaction or after an adequate reaction time and optionally after separation of the bound and free labelled components, the physical properties and/or the amount of the metal and/or a formed agglomerate containing said sol dispersed particles in the test sample or one of the derived fractions, which detection and/or determination provides a qualitative and/or quantitative indication of the component or components to be detected and/or determined.
31. The process according to claim 30, whereby the component or components of the reaction between a specific binding protein and the corresponding bindable substance are immunochemical components, such as haptens, antigens, or antibodies, comprising:
(a) employing labelled components, obtained by coupling directly or indirectly the desired immunochemical component to particles of an aqueous sol dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, having a particle size of at least 5 nm, and (b) detecting or determining after an adequate reaction time and optionally after separation of the bound and free labelled components, the physical properties and/or the amount of the metal and/or a formed agglomerate containing said metal particles in the test sample or one of the derived fractions, which detection and/or determination provides a qualitative and/or quantitative indication of the immunological component or components to be detected and/or determined.
32. The process according to claim 30, wherein one or more labelled components are used, obtained by coupling directly or indirectly the desired reactant to particles of a sol, having a particle size varying from 10 to 100 nm.
33. The process according to claim 30 wherein the labelled component is obtained by adding to a sol of a metal, a metal compound or polymer nuclei coated with a metal or metal compound, a certain amount of the immunochemical component to be labelled, which latter component completely or partially coats the sol particles, after which further coating may be carried out with an immunochemically inert polar macromolecule.
34. The process according to claim 30 wherein the labelled component is obtained by adding to a sol of a metal, a metal compound or polymer nuclei coated with a metal or a metal compound, one or more immunochemically inert hydro-philic macromolecules which coat the sol particles, after which the immunochemical component is coupled to the coating material.
35. The process according to claim 30 wherein the labelled component is obtained by:
(a) introducing a metal sol into an environment of monomers, causing said monomers to polymerize or co-polymerize in situ, so that coating of the sol particles results, and (b) subsequently coupling the immunochemical component to the polymeric material.
36. The process according to claim 30 wherein the sol particles are first protected by an inert hydrophilic macro-molecule, after which (CO)-polymerization occurs under the influence of an inorganic initiator.
37. The process according to claim 30 wherein the dis-persed particles are of a sol of gold, silver or platinum, or compounds of these metals, or iron or copper compounds.
38. The process according to claim 30 wherein after separation of the bound and the free labelled components, the physical properties and/or the amount of the metal is determined in the fraction containing the bound labelled component.
39. The process according to claim 30 wherein the immunochemical component or components to be determined is/are allowed to react with one or more insolubilized immunochemical component(s), before the labelled component or components is/
are added.
40. The process according to claim 30 wherein the bound labelled component or components is/are disengaged after separation of the free labelled component or components and the amount of the metal or metals is/are determined in the obtained liquid fraction.
41. The process according to claim 30 wherein two or more immunochemical components are determined in one test sample by use of two or more different labelled components.
42. The process according to claim 30 wherein the occurrance of a change in color or color intensity of the reaction mixture is observed or measured, which change is a qualitative or quantitative indication of the immunochemical, component to be determined.
43. A test kit, to be used for the detection and/or determination of one or more components of the reaction between a specific binding protein and a corresponding bindable sub-stance thereto in an aqueous medium according to a predetermined protocol, comprising:
(a) a metal-labelled component which has been obtained by coupling a component of said reaction to particles of an aqueous sol dispersion of a metal, metal compound or polymer nuclei coated with a metal or metal compound, which particles have a size of at least 5 nm;
(b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of (aa) a ligand capable of binding with the metal-labelled component (a);
(bb) a ligand capable of binding with a binding partner of the metal-labelled component (a);

(cc) a ligand capable of binding with at least one of the component(s) to be determined, and (dd) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined, and (c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction in an aqueous medium between a specific binding protein and a corresponding bindable substance thereto.
44. A test kit according to claim 43, in which the aqueous dispersion is a sol, having particles with a size varying from 10-100 nm, which are either directly coated by the component of said reaction or by an inert polymer, to which the desired component has been coupled.
45. The test kit according to claim 43, of which the labelled component is an immuno component.
46. The test kit according to claim 43, of which the labelled component is freeze-dried.
47. The test kit according to claim 43, of which the freeze-dried reagent contains also a buffer substance.
48. A method for the determination of a first component of an immunochemical reaction in an aqueous medium selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with (1) a known amount of a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, which particles have attached to their surfaces an immunochemical component which is immuno-chemically equivalent to said first component to be determined, and (2) a known amount of an insolubilized second component capable of reacting with either said first component to be determined or said reagent;

(b) allowing sufficient time for reaction to take place, whereby (1) a fraction of said first component to be determined bound to said insolubilized component, and (2) a fraction of said first component to be determined free from said insolubilized component are produced; and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
49. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with (1) a known amount of a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, which particles have attached to their surfaces (i) an immunochemical component immuno-chemically equivalent to said first component to be determined, and (ii) an immunochemically inert macromolecule, and (2) a known amount of an insolubilized second immunochemical component capable of reacting with either said first component to be determined or said reagent, (b) allowing sufficient time for reaction to take place, whereby (1) a fraction of said first component to be determined bound to said insolubilized component and (2) a fraction of said first component to be determined free from said insolubilized component are produced: and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
50. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with (1) a known amount of a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, which particles have a coating of an inert hydrophilic polymer or copolymer, the surface of each coated particle having attached to it an immunochemical com-ponent which is immunochemically equivalent to said first com-ponent, and (2) a known amount of an insolubilized second immunochemical component capable of reacting with either said first component to be determined or said reagent;
(b) allowing sufficient time for reaction to take place, whereby (1) a fraction of said first component to be determined bound to said insolubilized component and (2) a fraction of said first component to be determined free from said insolubilized component are produced; and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
51. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:

(a) contacting a sample containing the first component to be determined with (1) a known amount of reagent consisting essentially of metal sol dispersion having a particle size of at least 5 nm, which sol particles have attached to their surfaces a second immunochemical component of said reaction capable of reacting with said first component to be determined, and (2) a known amount of an insolubilized second immunochemical component which is immunochemically equivalent to said first component and capable of reacting with said reagent, (b) allowing sufficient time for reaction to take place, whereby (1) a fraction of said first component to be determined bound to said insolubilized component and (2) a fraction of said first component to be determined free from said insolubilized component are produced; and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
52. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with (1) a known amount of a reagent, said reagent consisting essentially of metal sol dispersion particles having sizes of at least 5 nm, which sol particles have attached to their surfaces (i) a second immunochemical component capable of reacting with said first component to be determined, and (ii) an immunochemically inert macromolecule and (2) a known amount of an insolubilized second immunochemical component which is immunochemically equivalent to said first component to be determined and capable of reacting with said reagent;

(b) allowing sufficient time for the reaction to take place, whereby (1) a fraction of said first component to be determined bound to said insolubilized component and (2) a fraction of said first component to be determined free from said insolubilized component are produced; and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
53. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corres-ponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with (1) a known amount of a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, which particles have a coating of an inert hydrophilic polymer or copolymer, the surface of each coated sol particle having attached to it a second immunochemical component of said reaction capable of reacting with said first component to be determined, and (2) a known amount of an insolubilized third immunochemical component which is immuno-chemically equivalent to said first component and capable of reacting with said reagent;
(b) allowing sufficient time for the reaction to take place, whereby a fraction of said first component to be determined bound to said insolubilized component and a fraction of said first component to be determined free from said insolubilized component are produced; and (c) determining the amount of the metal of the metal sol dispersion particles in one of said fractions, which is a measure of the amount of said first component to be determined in said sample.
54. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of its corresponding bindable substance, comprising:
(a) binding an amount of a second immunochemical component of said reaction capable of reacting with said first component to be determined, to the surface of a water-insoluble water-insuspensible, solid carrier, (b) contacting said bound second component with a sample containing the first component to be determined;
(c) allowing sufficient time for reaction to take place;
(d) contacting said bound reaction product of (c) with a known amount of a reagent consisting essentially of metal dispersion sol particles having a particle size of at least 5 nm, which sol particles have attached to their surface an immuno-chemical component capable of reacting with said first component to be determined;
(e) allowing sufficient time for reaction to take place, to bind a fraction of said reagent to that part of said bound second immunochemical component which has undergone the reaction in step (c), leaving a remaining fraction of said reagent free and not bound; and (f) determining the amount of the metal sol dispersion particles in the free reagent fraction or the bound reagent fraction, which is a measure of the amount of said first component to be determined in said sample.
55. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:

(a) binding an amount of a second immunochemical component capable of reacting with said first component to be determined, to the surface of a water-insoluble, water-insuspensible, solid carrier, (b) contacting said bound second component with a sample containing the first component to be determined, (c) allowing sufficient time for reaction to take place;
(d) contacting said bound reaction product of (c) with a known amount of reagent consisting essentially of metal sol dispersion particles, having a particle size of at least 5 nm, said sol particles having attached to their surfaces (i) an immunochemical component capable of reacting with said first component to be determined, and (ii) an immunochemically inert macromolecule;
(e) allowing sufficient time for reaction to take place to bind a fraction of said reagent to that part of said bound second component which has undergone the reaction in step (c), leaving a remaining fraction of said reagent free and not bound: and (f) determining the amount of the metal sol dispersion particles in the free reagent fraction or the bound reagent fraction, which is a measure of the amount of said component to be determined in said sample.
56. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) binding an amount of a second immunochemical component capable of reacting with said first component to be determined, to the surface of a water-insoluble, water-insuspensible, solid carrier:

(b) contacting said bound second component with a sample containing the first component to be determined;
(c) allowing sufficient time for reaction to take place;
(d) contacting said bound reaction product of (c) with a known amount of reagent consisting essentially of metal sol dispersion particles, having a particle size of at least 5 nm and having a coating of an inert hydrophilic polymer or co-polymer, the surface of each coated particle having attached to it an immunochemical component capable of reacting with said first component to be determined;
(e) allowing sufficient time for reaction to take place to bind a fraction of said reagent to that part of said bound second component which has undergone the reaction in step (c), leaving a remaining fraction of said reagent free and not bound; and (f) determining the amount of the metal sol dispersion particles in the free reagent fraction or the bound reagent fraction, which is a measure of the amount of said first component to be determined in said sample.
57. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with a known amount of a reagent, said reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, said sol particles having attached to their surfaces a second immunochemical com-ponent of said reaction capable of reacting with said first component to be determined;

(b) allowing sufficient time for reaction to take place; and (c) determining the color of the reaction solu-tion, which is a measure of the amount of said first component to be determined in said sample.
58. A method for the determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with a known amount of a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm, said sol particles having attached to their surfaces (i) a second immunochemical component of said reaction capable of reacting with said first component to be determined, and (ii) an immunochemically inert macro-molecule, (b) allowing sufficient time for a reaction to take place, and (c) determining the color of the reaction solution, which is a measure of the amount of said first com-ponent to be determined in said sample.
59. A method for the determination of a first com-ponent of an immunochemical reaction in an aqueous test medium selected from the group consisting of a specific binding protein and its corresponding bindable substance, comprising:
(a) contacting a sample containing the first component to be determined with a known amount of a reagent consisting of metal sol dispersion particles having a particle size of at least 5 nm, said sol particles having a coating of an inert hydrophilic polymer or copolymer, the surface of each coated particle having attached to it a second immunochemical component of said reaction capable of reacting with said first component to be determined;
(b) allowing sufficient time for a reaction to take place; and (c) determining the color of the reaction solution, which is a measure of the amount of said first component to be determined in said sample.
60. A method as in one of claims 48-50, wherein at least one of said components is drawn from the group consist-ing of antigens, haptens, and antibodies.
61. A method as in claim 48, wherein the metal sol dispersion particles are drawn from the group consisting of particles of platinum, gold, silver, copper, silver iodide, silver bromide, copper hydrous oxide, iron hydrous oxide, chromium hydroxide, aluminum hydroxide, aluminum hydrous oxide, chromium hydrous oxide, platinum, silver iodide, iron oxide, aluminum hydroxide, lead sulphide, barium sulfate, titanium dioxide, vanadium oxide, iron hydroxide, arsenic sulphide, manganese hydroxide and mercury sulphide.
62. A method as in claim 61, in which the metal sol dispersion particles are particles of gold.
63. A method for the immunochemical determination of human placental lactogen (HPL), comprising:
(a) binding a known amount of rabbit anti-HPL
immunoglobulin to the surface of a water-insoluble, water-insuspensible solid carrier;
(b) contacting said bound immunoglobulin with a sample solution containing the HPL to be determined;
(c) allowing sufficient time for an immunological reaction between the bound immunoglobulin and said HPL in the sample solution in step (b) to take place, to bind the HPL to be determined to the insolubilized rabbit anti- HPL, forming a first solid phase, and leaving a first liquid phase, (d) separating the first liquid and solid phases, (e) contacting said first reacted solid phase and bound HPL therein with a known amount of a reagent, said reagent consisting essentially of gold sol dispersion particles having a particle size of at least 5 nm, said particles having rabbit anti-HPL immunoglobulin attached to their surfaces, (f) allowing sufficient time for a second immunological reaction to take place, to bind said reagent to that part of said HPL solid phase bound immunoglobulin which has undergone the reaction in step (c), to form a second solid phase and a second liquid phase, (g) separating the second solid phase from the second liquid phase, and (h) determining the amount of gold sol in the second liquid phase or the second solid phase, which is a measure of the amount of HPL in said sample solution.
64. A method for the immunochemical determination of hepatitis Surface B antigen (HBsAg), comprising:
(a) binding a known amount of sheep anti-HBsAg immunoglobulin to the surface of a water-insoluble, water-insuspensible solid carrier;
(b) contacting said bound immunoglobulin with a sample solution containing the HBsAg to be determined, (c) allowing sufficient time for an immuno-logical reaction between the bound immunoglobulin and the HBsAg in the sample solution in step (b) to take place, to bind the HBsAg to be determined to the insolubilized sheep anti-HBsAg, forming a first solid phase, and leaving a first liquid phase, (d) separating the first liquid and solid phases, (e) contacting said first reacted solid phase and bound HBsAg therein with a known amount of a reagent having a particle size of at least 5 nm, said reagent consisting essentially of gold sol particles, said sol particles having anti-HBsAg immunoglobulin attached to their surfaces;
(f) allowing sufficient time for a second immunochemical reaction to take place, to bind said reagent to that part of said HBsAg solid phase bound immunoglobulin which has undergone the reaction in step (c), to form a second solid phase and a second liquid phase;
(g) separating the second solid phase from the second liquid phase; and (h) determining the amount of gold sol in the second liquid phase or the second solid phase, which is a measure of the amount of HBsAg in said sample solution.
65. A method for the immunochemical determination of testosterone in a liquid sample, comprising:
(a) binding a known amount of rabbit anti-testosterone immunoglobulin to the surface of a water-insoluble, water-insuspensible, solid carrier;
(b) contacting said bound rabbit anti-testoster-one with a sample solution containing the testosterone to be determined;
(c) allowing sufficient time for an immuno-logical reaction between the bound rabbit anti-testosterone immunoglobulin and the testosterone in the sample solution in step (b) to take place to bind the testosterone to be determined to the insolubilized rabbit anti-testosterone, forming a first solid phase, and leaving a first liquid phase;
(d) separating the first liquid and solid phases;

(e) contacting said first reacted solid phase and bound testosterone therein with a known amount of a reagent having a particle size of at least 5 nm, said reagent consisting essentially of silver sol dispersion particles, said sol particles having testosterone-ll.alpha.-hemisuccinyl-bovine serum albumin attached to their surfaces, to form a silver particle-testosterone-ll.alpha.-hemisuccinyl-bovine serum albumin conjugate, (f) allowing sufficient time for a second immunochemical reaction to take place to bind said reagent to that part of said solid phase bound rabbit anti-testosterone immunoglobulin which has not undergone the reaction in step (c), to form a second solid phase and a second liquid phase;
(g) separating the second solid phase from the second liquid phase; and (h) determining the amount of silver sol in the second solid phase or the second liquid phase, which is a measure of the amount of testosterone in said liquid sample.
66. A method for the immunochemical determination of the titer of human anti-Rubella sera, comprising:
(a) binding a known amount of Rubella antigen to the surface of a water-insoluble, water-insuspensible, solid carrier;
(b) contacting said bound Rubella antigen with a human serum sample containing the titer of human anti-Rubella sera to be determined;
(c) allowing sufficient time for an immuno-logical reaction between the bound Rubella antigen and the serum containing the titer of human anti-Rubella sera to be determined to take place to bind the anti-Rubella sera to the insolubilized Rubella antigen, forming a first solid phase, and leaving a first liquid phase;

(d) separating the first liquid and solid phases;

(e) contacting said first reacted solid phase and bound anti-Rubella titer therein with a known amount of a reagent, said reagent consisting essentially of gold sol dis-persion particles having a particle size of at least 5 nm, said sol particles having sheep anti-human immunoglobulin attached to their surfaces to form a gold particle sheep antihuman immunoglobulin conjugate, (f) allowing sufficient time for a second immunological reaction to take place to bind said reagent to the bound anti-Rubella titer solid phase, resulting in the binding of said reagent to that part of said bound antigen which has undergone the reaction in step (c), to form a second solid and a second liquid phase, (g) separating the second liquid and solid phases; and (h) determining the amount of gold sol in the second solid phase or the second liquid phase, which is a measure of the titer of the human anti-Rubella serum to be determined in said sample.
67. A method for the immunochemical determination of HCG, comprising:
(a) binding a known amount of a rabbit anti-HCG
immunoglobulin to the surface of a water-insoluble, water-insuspensible solid carrier;
(b) contacting said bound rabbit anti-HCG-immunoglobulin with a sample solution containing the HCG to be determined:
(c) allowing sufficient time for an immuno-logical reaction between the rabbit anti-HCG immunoglobulin and HCG in the sample solution in step (b) to take place, to bind the HCG to be determined to the insolubilized rabbit anti-HCG immunoglobulin, forming a first solid phase, and leaving a first liquid phase;

(d) separating the first solid phase from the first liquid phase;
(e) contacting said first solid phase and bound HCG with a known amount of a reagent consisting essentially of iron oxide sol dispersion particles having a particle size of at least 5 nm, said particles having rabbit anti-HCG immuno-globulin attached to their surfaces;
(f) allowing sufficient time for a second immunological reaction to occur to bind said reagent to that part of said HCG solid phase bound immunoglobulin which has undergone the reaction in step (c), to form a second solid phase and a second liquid phase;
(g) separating the second solid and second liquid phases; and (h) determining the amount of iron sol in the second solid phase or the second liquid phase, which is a measure of the amount of the HCG to be determined in said sample solution.
68. A method for the immunochemical determination of HCG, comprising:
(a) contacting an aqueous sample containing the HCG to be determined with a known amount of a reagent consisting essentially of gold sol dispersion particles having a particle size of at least 5 nm, said sol particles having rabbit anti-HCG immunoglobulin attached to their surfaces;
(b) allowing sufficient time for an immuno-logical reaction between said reagent and any HCG in the sample solution to take place; and (c) determining the color of the sample solution, which is a measure of the amount of HCG to be determined in said sample solution.
69. A method for the determination of HCG, comprising:
(a) binding a known amount of HCG receptor protein to the surface of a water-insoluble, water-insuspensible solid carrier:
(b) contacting said bound receptor protein with a sample solution containing the HCG to be determined:
(c) allowing sufficient time for an immuno-logical reaction between the insolubilized HCG receptor protein and the HCG to be determined:
(d) adding a known amount of reagent to said sample solution, said reagent consisting essentially of gold sol dispersion particles having a particle size of at least 5 nm and having HCG attached to their surfaces:
(e) allowing sufficient time for a reaction to take place between (1) the gold sol dispersion reagent and (2) the insolubilized HCG receptor protein not bound to HCG, to form a solid phase containing a fraction of gold sol dispersion reagent bound to insolubilized HCG receptor protein, and a liquid phase of unbound and free gold dispersion reagent:
(f) separating the liquid and solid phases, and (g) determining the amount of gold sol in either the solid or liquid phase, which is a measure of the amount of HCG in said sample solution.
70. A method for the immunochemical determination of HCG, comprising:
(a) binding a known amount of HCG receptor protein to the surface of a water-insoluble, water-insuspensible solid carrier:
(b) contacting said bound receptor protein with a sample solution containing the unknown HCG to be determined:

(c) allowing sufficient time for an immuno-chemical reaction between the bound receptor protein and the HCG in the sample solution to take place, to bind the HCG
to be determined to the insolubilized HCG receptor protein, forming a first solid phase, and leaving a first liquid phase;
(d) separating the first solid phase from the first liquid phase, (e) contacting said first solid phase and insolubilized HCG therein with a known amount of a reagent consisting essentially of gold sol dispersion particles having rabbit anti-HCG immunoglobulin attached to their surfaces having a particle size of at least 5 nm;
(f) allowing sufficient time for a second immunological reaction to occur to bind said reagent to that part of said insolubilized HCG which has undergone the reaction in step (c), to form a second solid phase and a second liquid phase;
(g) separating the second solid phase from the second liquid phase; and (h) determining the amount of gold sol in the second solid phase or the second liquid phase, which is a measure of the HCG to be determined in said sample solution.
71. Test kit, to be used for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consist-ing of a specific binding protein and a corresponding bindable substance thereto, according to a predetermined protocol, comprising:
(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces either a component immunochemically similar to said first component to be determined, or a binding partner of the first component, and (b) directions for the performance of a protocol for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, using said reagent (a).
72. Test kit, to be used for the detection and/or determination of a first component of an immunochemical eaction in an aqueous medium, selected from the group con-sisting of a specific binding protein and a corresponding bind-able substance thereto, according to a predetermined protocol, comprising:
(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces (1) either a component immunochemically similar to said first component, or a binding partner to said first component, and (2) an immunochemically inert macromolecule, and (b) directions for the performance of a protocol for the detection and/or determination of first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a correspond-ing bindable substance thereto, using said reagent (a).
73. Test kit, to be used for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consist-ing of a specific binding protein and a corresponding bindable substance thereto, according to a predetermined protocol, comprising:

(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces a coating of an inert hydrophilic polymer or copolymer, the surface of each coated particle having attached to it a component selected from the group consisting of a component immunochemically equivalent to said first component, or a binding partner to said first component, and (b) directions for the performance of a protocol for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, using said reagent (a).
74. Test kit according to claim 71, 72 or 73, in which the dispersion is a gold, silver or iron oxide sol.
75. Test kit, according to claim 71, in which the particles range from 10 - 100 nm in size.
76. Test kit according to claim 71 also containing an insolubilized immunocomponent, in which the immunocomponent is selected from the group consisting of (1) a component immunochemically similar to the component to be determined, or (2) a binding partner of the component to be determined.
77. Test kit according to claim 76, in which said reagent containing metal dispersed particles is freeze-dried.
78. Test kit according to claim 77, in which a buffer is included with said reagent.
79- A method as in claims 48, 49 or 50, in which said particles are gold, silver, or iron oxide sols.
80. A method as in claim 48, in which said particles range in size from 10 - 100 nm.
81. Test kit, to be used for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consist-ing of a specific binding protein and a corresponding bindable substance thereto, according to a predetermined protocol, comprising:
(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces either a component immunochemically similar to said first component to be determined, or a binding partner of the first component, and (b) directions for the performance of a protocol for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, using said reagent (a), which protocol comprises:
(1) contacting an aqueous sample having a first color and containing the component to be detected and/or determined with a solution containing reagent (a) for a sufficient time to allow an immunochemical reaction between said component to be detected and/or determined and said reagent (a) to take place, to form a solution of formed agglomerate containing said dispersed particles whereby the reacted solution has a second color, and (2) detecting and/or determining the presence or amount of said agglomerate by observing the difference between the first color and the second color.
82. Test kit, to be used for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, according to a predetermined protocol, comprising:
(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces (1) either a component immunochemically similar to said first component, or a binding partner to said first component, and (2) an immunochemically inert macromolecule, and (b) directions for the performance of a protocol for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, using said reagent (a), which protocol comprises:
(1) contacting an aqueous sample having a first color containing the component to be detected and/or determined with a solution containing reagent (a) for a sufficient time to allow an immunochemical reaction between said component to be detected and/or determined and said reagent (a) to take place to form a solution of formed agglomerate containing said dispersed particles whereby the reacted solution has a second color, and (2) detecting and/or determining the presence or amount of said agglomerate by observing the difference between the first color and the second color.
83. Test kit, to be used for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, according to a predetermined protocol, comprising:
(a) a reagent consisting essentially of metal sol dispersion particles having a particle size of at least 5 nm and having attached to their surfaces a coating of an inert hydrophilic polymer or copolymer, the surface of each coated particle having attached to it a component selected from the group consisting of a component immunochemically equivalent to said first component, or a binding partner to said first com-ponent; and (b) directions for the performance of a protocol for the detection and/or determination of a first component of an immunochemical reaction in an aqueous medium, selected from the group consisting of a specific binding protein and a corresponding bindable substance thereto, using said reagent (a), which protocol comprises:
(1) contacting an aqueous sample having a first color containing the component to be detected and/or determined with a solution containing reagent (a) for a sufficient time to allow an immunochemical reaction between said component to be detected and/or determined and said reagent (a) to take place, to form a solution of formed agglomerate containing said dispersed particles whereby the reacted solution has a second color; and (2) detecting and/or determining the presence or amount of said agglomerate by observing the difference between the first color and the second color.
CA000331816A 1978-07-13 1979-07-13 Dispersed metal particle labelled assay Expired CA1135183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL7807532A NL7807532A (en) 1978-07-13 1978-07-13 METAL IMMUNO TEST.
NL78.07532 1978-07-13

Publications (1)

Publication Number Publication Date
CA1135183A true CA1135183A (en) 1982-11-09

Family

ID=19831245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000331816A Expired CA1135183A (en) 1978-07-13 1979-07-13 Dispersed metal particle labelled assay

Country Status (19)

Country Link
US (1) US4313734A (en)
EP (1) EP0007654B1 (en)
JP (1) JPS5515100A (en)
AT (1) ATE786T1 (en)
AU (1) AU530217B2 (en)
CA (1) CA1135183A (en)
DE (1) DE2962333D1 (en)
DK (1) DK159799C (en)
ES (1) ES482488A1 (en)
FI (1) FI77120C (en)
GR (1) GR73524B (en)
HU (1) HU181659B (en)
IE (1) IE48467B1 (en)
IL (1) IL57722A (en)
MX (1) MX164526B (en)
NL (1) NL7807532A (en)
PH (1) PH16420A (en)
PT (1) PT69900A (en)
ZA (1) ZA793276B (en)

Families Citing this family (369)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
NL8000173A (en) * 1980-01-11 1981-08-03 Akzo Nv USE OF WATER-DISPERSIBLE HYDROPHOBIC DYES AS LABELS IN IMMUNOCHEMICAL TESTS.
JPS5745454A (en) * 1980-09-02 1982-03-15 Fuji Photo Film Co Ltd Immunochemical measuring method for various minor components
US4420558A (en) * 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
GB2095258B (en) * 1981-03-19 1984-09-05 Janssen Pharmaceutica Nv A bright field light microscopic method of localizing tissue antigens
JPS5832167A (en) * 1981-08-20 1983-02-25 Sekisui Chem Co Ltd Immunochemical measuring method
US4454233A (en) * 1981-10-21 1984-06-12 Wang Associates Method of tagged immunoassay
GB8331514D0 (en) * 1983-11-25 1984-01-04 Janssen Pharmaceutica Nv Visualization method
US4703017C1 (en) * 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4752567A (en) * 1984-06-21 1988-06-21 Janssen Pharmaceutica N.V. Method of visualizing individual submicroscopic metal particles
GB8415998D0 (en) * 1984-06-22 1984-07-25 Janssen Pharmaceutica Nv Staining method
US5958790A (en) * 1984-12-20 1999-09-28 Nycomed Imaging As Solid phase transverse diffusion assay
DE3666982D1 (en) * 1985-08-19 1989-12-21 Akzo Nv Device for the carrying out of an immunochemical determination
US4868104A (en) * 1985-09-06 1989-09-19 Syntex (U.S.A.) Inc. Homogeneous assay for specific polynucleotides
JPS62197425A (en) * 1986-02-25 1987-09-01 Toyo Soda Mfg Co Ltd Production of spherical thermoplastic resin
US5200270A (en) * 1986-02-25 1993-04-06 Toyo Soda Manufacturing Co., Ltd. Carrier for a biologically active component for immunoassay or enzymatic reaction
US4794089A (en) * 1986-03-25 1988-12-27 Midwest Research Microscopy, Inc. Method for electronic detection of a binding reaction
US5137827A (en) * 1986-03-25 1992-08-11 Midwest Research Technologies, Inc. Diagnostic element for electrical detection of a binding reaction
US5514602A (en) * 1986-06-09 1996-05-07 Ortho Diagnostic Systems, Inc. Method of producing a metal sol reagent containing colloidal metal particles
AU7385387A (en) * 1986-06-09 1987-12-10 Ortho Diagnostic Systems Inc. Immunoassay using detection of colloidal gold
AU602694B2 (en) * 1986-06-09 1990-10-25 Ortho Diagnostic Systems Inc. Improved colloidal gold membrane assay
JP2591750B2 (en) * 1986-06-26 1997-03-19 オ−ソ・ダイアグノステイツク・システムズ・インコ−ポレ−テツド Immunoassay system
US5017009A (en) * 1986-06-26 1991-05-21 Ortho Diagnostic Systems, Inc. Scattered total internal reflectance immunoassay system
JPH0611870B2 (en) * 1986-06-27 1994-02-16 徳山曹達株式会社 Inorganic compound / dye composite particles
JPS63127160A (en) * 1986-06-30 1988-05-31 Sukeyasu Yoneda Detection of specific protein
US4888248A (en) * 1986-07-01 1989-12-19 Hidefumi Hirai Colloidal metal dispersion, and a colloidal metal complex
CA1317206C (en) * 1986-09-22 1993-05-04 Takeyuki Kawaguchi Method for detecting a component of a biological system and detection device and kit therefor
US5238810A (en) * 1986-09-22 1993-08-24 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus thereof
WO1988002118A1 (en) * 1986-09-22 1988-03-24 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus therefor
CA1301645C (en) * 1986-10-08 1992-05-26 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostictest for the identification of group a streptococci
US4880751A (en) * 1986-10-31 1989-11-14 Board Of Regents, The University Of Texas System Immunoglobulin adsorption
AU593151B2 (en) * 1986-11-12 1990-02-01 Molecular Diagnostics, Inc. Method for the detection of nucleic acid hybrids
US4879220A (en) * 1986-11-18 1989-11-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Crosslinking receptor-specific probes for electron microscopy
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
CA1340803C (en) * 1987-03-09 1999-10-26 Janssen Pharmaceutica N.V. Method for depositing metal particles on a marker
US5491098A (en) * 1987-03-09 1996-02-13 Janssen Pharmaceutica N.V. Method for depositing metal particles on a marker
USRE38430E1 (en) 1987-03-27 2004-02-17 Becton, Dickinson And Company Solid phase chromatographic immunoassay
DE560410T1 (en) 1987-04-27 2001-12-20 Unilever Nv Test device for carrying out specific binding tests.
US4954452A (en) * 1987-07-09 1990-09-04 Abbott Laboratories Non-metal colloidal particle immunoassay
US5120643A (en) * 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
JPH021557A (en) * 1987-08-05 1990-01-05 Teijin Ltd Detection of biocomponent
US4853335A (en) * 1987-09-28 1989-08-01 Olsen Duane A Colloidal gold particle concentration immunoassay
US5393658A (en) * 1987-09-28 1995-02-28 New Horizons Diagnostics Corporation Immunoassay method for the rapid identification of detergent treated antigens
JP2581566B2 (en) * 1987-09-30 1997-02-12 和光純薬工業株式会社 Iron colloid-labeled antibody, method for producing the same, and histocytochemical detection method using the same
US4859612A (en) * 1987-10-07 1989-08-22 Hygeia Sciences, Inc. Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite
DE3878167T2 (en) * 1987-11-16 1993-05-27 Janssen Pharmaceutica Nv GENERAL APPLICABLE DETECTING SYSTEM BASED ON ULTRA-SMALL COLLOIDAL METAL PARTICLES.
NL8702769A (en) * 1987-11-19 1989-06-16 Holland Biotechnology METHOD FOR DETERMINING A TEST SAMPLE OF COMPONENTS OF THE REACTION BETWEEN A SPECIFIC BINDING PROTEIN AND THE ACCOMPANYING BINDABLE SUBSTANCE USING AT LEAST ONE BRANDED COMPONENT, METHOD FOR PREPARING THE MARKED COMPONENT, AND TESTING COMPONENT
US4948725A (en) * 1987-12-10 1990-08-14 University Of Florida Research Foundation, Inc. Novel type VI bacterial Fc receptors
US5085984A (en) * 1987-12-10 1992-02-04 University Of Florida Research Foundation, Inc. Novel type VI bacterial Fc receptors
US4979821A (en) * 1988-01-27 1990-12-25 Ortho Diagnostic Systems Inc. Cuvette for receiving liquid sample
US4952517A (en) * 1988-02-08 1990-08-28 Hygeia Sciences, Inc. Positive step immunoassay
GB8804669D0 (en) * 1988-02-27 1988-03-30 Medical Res Council Immobilisation of haptens
FR2680374B1 (en) * 1988-03-25 1993-11-12 Bioprobe Systems Sa METHOD FOR COLORING NUCLEIC ACIDS DETECTED BY NON-RADIOACTIVE LABELING AND SET OF REAGENTS FOR IMPLEMENTING THIS METHOD.
US5202267A (en) * 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5501986A (en) * 1988-04-06 1996-03-26 E. I. Du Pont De Nemours And Company Piezoelectric specific binding assay with mass amplified reagents
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5281522A (en) * 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
US5252459A (en) * 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
US4995402A (en) * 1988-10-12 1991-02-26 Thorne, Smith, Astill Technologies, Inc. Medical droplet whole blood and like monitoring
US5079172A (en) * 1988-11-04 1992-01-07 Board Of Trustees Operating Michigan State University Method for detecting the presence of antibodies using gold-labeled antibodies and test kit
ES2080740T3 (en) * 1988-11-14 1996-02-16 Akzo Nobel Nv AQUEOUS SUSPENSION FOR DIAGNOSTIC TESTS.
US5294370A (en) * 1988-11-15 1994-03-15 Hbt Holland Biotechnology B.V. Selenium or tellurium elemental hydrosols and their preparation
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) * 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
ES2088427T3 (en) * 1989-03-21 1996-08-16 Hygeia Sciences Ltd SIMULTANEOUS TEST OF TWO ANALYTIES.
GB8909478D0 (en) * 1989-04-26 1989-06-14 Bradwell Arthur R Radial immunodiffusion and like techniques
US5079029A (en) * 1989-06-16 1992-01-07 Saunders George C Fingerprint detection
CA2026409C (en) * 1989-09-29 2004-11-09 Ernest G. Schutt Method of producing a reagent containing a narrow distribution of colloidal particles of a selected size and the use thereof
US5075078A (en) * 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device
GR1000686B (en) * 1989-11-16 1992-10-08 Ortho Diagnostic Systems Inc Method of producing a metal for reagent containing colloidal metal particles of a preselected size
US5252496A (en) * 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5141850A (en) * 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
AU7688191A (en) * 1990-03-28 1991-10-21 Board Of Regents, The University Of Texas System Production of electrophoretically-uniform protein-colloidal gold complexes
US5334538A (en) * 1990-11-26 1994-08-02 V-Tech, Inc. Gold sol immunoassay system and device
US5294369A (en) * 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
GB9028038D0 (en) * 1990-12-24 1991-02-13 Nycomed Pharma As Test method and reagent kit therefor
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5869345A (en) * 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
US5877028A (en) 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
US5468648A (en) * 1991-05-29 1995-11-21 Smithkline Diagnostics, Inc. Interrupted-flow assay device
US5196350A (en) * 1991-05-29 1993-03-23 Omnigene, Inc. Ligand assay using interference modulation
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
EP0519250A3 (en) * 1991-06-10 1993-06-02 Miles Inc. Microparticle-labeled binding assay analyzed by microwave spectroscopy
ZA923679B (en) * 1991-06-21 1993-01-27 Pro Soma Sarl Diagnostic method
US5837552A (en) * 1991-07-22 1998-11-17 Medifor, Ltd. Surface-enhanced analytical procedures and substrates
EP0598003B1 (en) * 1991-07-22 1999-02-10 Kloehn Instruments, Ltd. Substrate for surface-enhanced analytical procedures, and substrates prepared for specific procedures
US5518887A (en) * 1992-03-30 1996-05-21 Abbott Laboratories Immunoassays empolying generic anti-hapten antibodies and materials for use therein
US5310647A (en) * 1992-04-01 1994-05-10 Cherrystone Corporation Detection and measurement of destructive and polymer forming enzymes by colloidal flocculation
US5395754A (en) * 1992-07-31 1995-03-07 Hybritech Incorporated Membrane-based immunoassay method
TW239881B (en) * 1992-12-22 1995-02-01 Sienna Biotech Inc
US6200820B1 (en) 1992-12-22 2001-03-13 Sienna Biotech, Inc. Light scatter-based immunoassay
FI92882C (en) * 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Disposable test strip and process for its manufacture
US5340746A (en) * 1993-01-08 1994-08-23 Minnesota Mining And Manufacturing Company Composite reactive articles for the determination of cyanide
US5424193A (en) * 1993-02-25 1995-06-13 Quidel Corporation Assays employing dyed microorganism labels
US5384265A (en) * 1993-03-26 1995-01-24 Geo-Centers, Inc. Biomolecules bound to catalytic inorganic particles, immunoassays using the same
US5637508A (en) * 1993-03-26 1997-06-10 Geo-Centers, Inc. Biomolecules bound to polymer or copolymer coated catalytic inorganic particles, immunoassays using the same and kits containing the same
US5837546A (en) * 1993-08-24 1998-11-17 Metrika, Inc. Electronic assay device and method
US6653066B1 (en) 1994-06-17 2003-11-25 Trinity Biotech Device and method for detecting polyvalent substances
US6818199B1 (en) * 1994-07-29 2004-11-16 James F. Hainfeld Media and methods for enhanced medical imaging
EP0722087B1 (en) * 1994-07-29 2005-06-29 Mitsubishi Kagaku Iatron, Inc. Measurement system using whole blood
US6121425A (en) * 1994-07-29 2000-09-19 Nanoprobes, Inc. Metal-lipid molecules
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
EP0724909A1 (en) 1994-11-28 1996-08-07 Akzo Nobel N.V. Sample collection device
US5569608A (en) * 1995-01-30 1996-10-29 Bayer Corporation Quantitative detection of analytes on immunochromatographic strips
DE19511276C2 (en) * 1995-03-27 1999-02-18 Immuno Ag Adjuvant based on colloidal iron compounds
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US7635597B2 (en) 1995-08-09 2009-12-22 Bayer Healthcare Llc Dry reagent particle assay and device having multiple test zones and method therefor
US5851777A (en) * 1996-02-05 1998-12-22 Dade Behring Inc. Homogeneous sol-sol assay
AU2121497A (en) * 1996-02-22 1997-09-10 Dexall Biomedical Labs, Inc. Non-captive substrate liquid phase immunoassay
WO1997034150A1 (en) * 1996-03-14 1997-09-18 Abbott Laboratories Binding members extending from particles for immunoassay
US5753517A (en) * 1996-03-29 1998-05-19 University Of British Columbia Quantitative immunochromatographic assays
JP2000510582A (en) 1996-04-25 2000-08-15 ゼニコン・サイエンシーズ・コーポレーション Analyte assays using particulate labeling
US6586193B2 (en) 1996-04-25 2003-07-01 Genicon Sciences Corporation Analyte assay using particulate labels
US5968839A (en) * 1996-05-13 1999-10-19 Metrika, Inc. Method and device producing a predetermined distribution of detectable change in assays
US5750411A (en) * 1996-06-03 1998-05-12 Bayer Corporation Sol particle decay protection immunoassay
DE19622628A1 (en) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilization of metal conjugates
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6984491B2 (en) * 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5945345A (en) * 1996-08-27 1999-08-31 Metrika, Inc. Device for preventing assay interference using silver or lead to remove the interferant
US6001658A (en) * 1996-09-13 1999-12-14 Diagnostic Chemicals Limited Test strip apparatus and method for determining presence of analyte in a fluid sample
US5856194A (en) 1996-09-19 1999-01-05 Abbott Laboratories Method for determination of item of interest in a sample
US5795784A (en) 1996-09-19 1998-08-18 Abbott Laboratories Method of performing a process for determining an item of interest in a sample
US6979576B1 (en) * 1997-07-25 2005-12-27 Shu-Ching Cheng Methods of use of one step immunochromatographic device for Streptococcus A antigen
US6194221B1 (en) * 1996-11-19 2001-02-27 Wyntek Diagnostics, Inc. Hybrid one-step immunochromatographic device and method of use
US6413786B1 (en) * 1997-01-23 2002-07-02 Union Biometrica Technology Holdings, Inc. Binding assays using optical resonance of colloidal particles
US5879951A (en) * 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US20050101032A1 (en) * 1997-02-10 2005-05-12 Metrika, Inc. Assay device, composition, and method of optimizing assay sensitivity
US6180415B1 (en) * 1997-02-20 2001-01-30 The Regents Of The University Of California Plasmon resonant particles, methods and apparatus
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6852252B2 (en) 1997-03-12 2005-02-08 William Marsh Rice University Use of metalnanoshells to impede the photo-oxidation of conjugated polymer
US6344272B1 (en) * 1997-03-12 2002-02-05 Wm. Marsh Rice University Metal nanoshells
US6103536A (en) 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
US5939252A (en) * 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
US6258548B1 (en) 1997-06-05 2001-07-10 A-Fem Medical Corporation Single or multiple analyte semi-quantitative/quantitative rapid diagnostic lateral flow test system for large molecules
US20050037397A1 (en) * 2001-03-28 2005-02-17 Nanosphere, Inc. Bio-barcode based detection of target analytes
US6974669B2 (en) * 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6752988B1 (en) * 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US6277399B1 (en) * 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6437563B1 (en) 1997-11-21 2002-08-20 Quantum Design, Inc. Method and apparatus for making measurements of accumulations of magnetically susceptible particles combined with analytes
US6699724B1 (en) * 1998-03-11 2004-03-02 Wm. Marsh Rice University Metal nanoshells for biosensing applications
US6428811B1 (en) 1998-03-11 2002-08-06 Wm. Marsh Rice University Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery
US6127130A (en) 1998-03-13 2000-10-03 The United States Of America As Represented By The Secretary Of The Navy Multiassay method for determining the concentrations of antigens and interferants
CA2323725A1 (en) 1998-03-20 1999-09-23 The Rockefeller University Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
ES2501241T3 (en) * 1998-03-30 2014-10-01 Orasure Technologies, Inc. Collection device for oral fluid analysis
US8062908B2 (en) * 1999-03-29 2011-11-22 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US6303081B1 (en) * 1998-03-30 2001-10-16 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US20060019404A1 (en) * 1998-05-06 2006-01-26 Blatt Joel M Quantitative assay with extended dynamic range
EP2000803A1 (en) 1998-11-30 2008-12-10 Nanosphere, Inc. Nanoparticles with Polymer Shells
EP1147416B1 (en) * 1999-01-23 2013-05-29 Minerva Biotechnologies Corporation Assays involving colloids and non-colloidal structures
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
US8406498B2 (en) 1999-01-25 2013-03-26 Amnis Corporation Blood and cell analysis using an imaging flow cytometer
US8885913B2 (en) 1999-01-25 2014-11-11 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
US7450229B2 (en) * 1999-01-25 2008-11-11 Amnis Corporation Methods for analyzing inter-cellular phenomena
US20060257884A1 (en) * 2004-05-20 2006-11-16 Amnis Corporation Methods for preparing and analyzing cells having chromosomal abnormalities
US8131053B2 (en) * 1999-01-25 2012-03-06 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
US6136044A (en) * 1999-02-03 2000-10-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stable coloring by in situ formation of micro-particles
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
JP4219491B2 (en) * 1999-06-18 2009-02-04 富士フイルム株式会社 Dry analysis method and dry analysis element
JP4212189B2 (en) * 1999-07-12 2009-01-21 富士フイルム株式会社 Dry analysis method and dry analysis element
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US8497131B2 (en) * 1999-10-06 2013-07-30 Becton, Dickinson And Company Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules
US7192778B2 (en) * 1999-10-06 2007-03-20 Natan Michael J Surface enhanced spectroscopy-active composite nanoparticles
US6306665B1 (en) 1999-10-13 2001-10-23 A-Fem Medical Corporation Covalent bonding of molecules to an activated solid phase material
AU774593C (en) 2000-01-13 2005-06-23 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
DE10003734A1 (en) * 2000-01-28 2001-08-02 Bosch Gmbh Robert Detection method and device
US20020004246A1 (en) * 2000-02-07 2002-01-10 Daniels Robert H. Immunochromatographic methods for detecting an analyte in a sample which employ semiconductor nanocrystals as detectable labels
US6998273B1 (en) 2000-02-09 2006-02-14 A-Fem Medical Corporation Collection device for lateral flow chromatography
US6365417B1 (en) 2000-02-09 2002-04-02 A-Fem Medical Corporation Collection device for lateral flow chromatography
AU783559B2 (en) * 2000-03-09 2005-11-10 Colorado State University Research Foundation Use of recombinant antigens to determine the immune status of an animal
US6699722B2 (en) 2000-04-14 2004-03-02 A-Fem Medical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
AU2001275475A1 (en) * 2000-06-12 2001-12-24 Genicon Sciences Corporation Assay for genetic polymorphisms using scattered light detectable labels
AU2001270078A1 (en) * 2000-06-23 2002-01-08 Minerva Biotechnologies Corporation Tandem signaling assay
FR2810739B1 (en) * 2000-06-26 2007-01-26 Centre Nat Rech Scient ELECTROCHEMICAL IMMUNODOSIS USING COLLOIDAL METAL MARKERS
AU7687001A (en) 2000-07-11 2002-01-21 Nanospherre Inc Method of detection by enhancement of silver staining
WO2002006837A1 (en) * 2000-07-14 2002-01-24 Matsushita Electric Industrial Co., Ltd. Particle-labeled protein and immuno-chromatograph using the same
EP1309865B1 (en) * 2000-08-10 2009-06-10 bioMerieux B.V Moving droplet diagnostic assay
US7615340B2 (en) * 2000-10-03 2009-11-10 Minerva Biotechnologies Corporation Electronic detection of interaction and detection of interaction based on the interruption of flow
AU2002213157A1 (en) 2000-10-12 2002-04-22 Amnis Corporation System and method for high numeric aperture imaging systems
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
JP2002202310A (en) * 2000-10-27 2002-07-19 Morinaga Milk Ind Co Ltd Substance detecting reagent and substance detecting method
WO2002102405A1 (en) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation The use of bacterial phage associated lytic enzymes to prevent food poisoning
US7135296B2 (en) * 2000-12-28 2006-11-14 Mds Inc. Elemental analysis of tagged biologically active materials
US7700295B2 (en) * 2000-12-28 2010-04-20 Mds Sciex Elemental analysis of tagged biologically active materials
AU2002215784B2 (en) * 2000-12-28 2007-09-13 Dh Technologies Development Pte. Ltd. Elemental analysis of tagged biologically active materials
US6861263B2 (en) 2001-01-26 2005-03-01 Surromed, Inc. Surface-enhanced spectroscopy-active sandwich nanoparticles
CA2439307A1 (en) * 2001-02-23 2002-09-06 Genicon Sciences Corporation Methods for providing extended dynamic range in analyte assays
US20060040286A1 (en) * 2001-03-28 2006-02-23 Nanosphere, Inc. Bio-barcode based detection of target analytes
WO2002078906A2 (en) * 2001-03-29 2002-10-10 Cellect Technologies Corp. Methods devices and systems for sorting and separating particles
US20030113740A1 (en) * 2001-04-26 2003-06-19 Mirkin Chad A. Oligonucleotide-modified ROMP polymers and co-polymers
US7147687B2 (en) * 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
AU2002239726A1 (en) 2001-05-25 2002-12-09 Northwestern University Non-alloying core shell nanoparticles
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
US7270959B2 (en) 2001-07-25 2007-09-18 Oakville Hong Kong Company Limited Specimen collection container
US7300633B2 (en) * 2001-07-25 2007-11-27 Oakville Hong Kong Company Limited Specimen collection container
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US7393696B2 (en) * 2001-09-28 2008-07-01 Aspenbio Pharma, Inc. Bovine pregnancy test
EP1300684A1 (en) * 2001-10-08 2003-04-09 Barts and The London National Health Service Trust Homogenous ligand binding assay
TWI301164B (en) * 2001-10-12 2008-09-21 Phild Co Ltd
US6562403B2 (en) * 2001-10-15 2003-05-13 Kansas State University Research Foundation Synthesis of substantially monodispersed colloids
US6867005B2 (en) 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
JP4220397B2 (en) 2001-11-09 2009-02-04 ナノスフェアー インコーポレイテッド Bioconjugate-nanoparticle probe
US20030104439A1 (en) * 2001-11-30 2003-06-05 Finch Rosalynde J. Methods of identifying cellular target molecules
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
DE60207196T2 (en) * 2002-04-09 2006-07-20 Cholestech Corp., Hayward Method and apparatus for quantification of high density lipoprotein cholesterol
US20030211488A1 (en) * 2002-05-07 2003-11-13 Northwestern University Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection
US7238519B2 (en) 2002-06-07 2007-07-03 Cholestech Corporation Automated immunoassay cassette, apparatus and method
EP1369473B1 (en) * 2002-06-07 2009-01-21 Cholestech Corporation Automated cassete module for an apparatus for conducting immunoassays and use thereof
CA2490765A1 (en) * 2002-06-27 2004-01-08 Georgia Tech Research Corporation Nano-sized optical fluorescence labels and uses thereof
CA2490413C (en) * 2002-07-02 2011-08-30 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
CN1697972B (en) 2002-08-13 2010-09-29 N-Dia公司 Devices and methods for detecting amniotic fluid in vaginal secretions
ES2525318T3 (en) * 2002-10-11 2014-12-22 Zbx Corporation Diagnostic devices
JP2006504755A (en) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Pyridazine compounds as GSK-3 inhibitors
US7560272B2 (en) * 2003-01-04 2009-07-14 Inverness Medical Switzerland Gmbh Specimen collection and assay container
US20050130174A1 (en) * 2003-02-27 2005-06-16 Nanosphere, Inc. Label-free gene expression profiling with universal nanoparticle probes in microarray assay format
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
US7341841B2 (en) * 2003-07-12 2008-03-11 Accelr8 Technology Corporation Rapid microbial detection and antimicrobial susceptibility testing
AU2004273783A1 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
US7517495B2 (en) * 2003-08-25 2009-04-14 Inverness Medical Switzerland Gmbh Biological specimen collection and analysis system
US20050141843A1 (en) * 2003-12-31 2005-06-30 Invitrogen Corporation Waveguide comprising scattered light detectable particles
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
US7638093B2 (en) * 2004-01-28 2009-12-29 Dnt Scientific Research, Llc Interrupted flow rapid confirmatory immunological testing device and method
US20050255533A1 (en) * 2004-02-10 2005-11-17 Brendan Bioscience, Llc Comprehensive food allergy test
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US8953866B2 (en) 2004-03-16 2015-02-10 Amnis Corporation Method for imaging and differential analysis of cells
US8103080B2 (en) * 2004-03-16 2012-01-24 Amnis Corporation Method for imaging and differential analysis of cells
ATE538138T1 (en) 2004-03-16 2012-01-15 Amnis Corp IMAGING-BASED QUANTIFICATION OF MOLECULAR TRANSLOCATION
EP1733233B1 (en) * 2004-03-30 2012-12-12 GE Healthcare Bio-Sciences Corp. Lateral flow format, materials and methods
US7319032B2 (en) * 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
US7763454B2 (en) 2004-07-09 2010-07-27 Church & Dwight Co., Inc. Electronic analyte assaying device
EP1800126B1 (en) * 2004-09-08 2014-12-17 The United States of America as represented by the Secretary of Health and Human Services, NIH Compositions and methods for the detection of hiv-1/hiv-2 infection
US7727775B2 (en) * 2004-10-25 2010-06-01 Willson Richard C Optical microlabels: shapes and reflectors
US7709208B2 (en) * 2004-11-08 2010-05-04 New York University Methods for diagnosis of major depressive disorder
EP2395109A1 (en) 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
US7387890B2 (en) * 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
US9568471B2 (en) 2005-01-25 2017-02-14 The Johns Hopkins University Plasmodium diagnostic assay device
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method
US7396689B2 (en) * 2005-02-04 2008-07-08 Decision Biomarkers Incorporated Method of adjusting the working range of a multi-analyte assay
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
EP1869468B1 (en) * 2005-03-29 2010-05-05 Inverness Medical Switzerland GmbH Colloidal metal conjugates
US20060246513A1 (en) * 2005-05-02 2006-11-02 Bohannon Robert C Method and device to detect the presence of analytes in a sample
AU2006321289B2 (en) 2005-05-23 2011-12-08 Phadia Ab Two step lateral flow assay methods and devices
US11506674B2 (en) 2005-07-29 2022-11-22 Princeton Biomeditech Corporation Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
US8987004B2 (en) * 2005-08-02 2015-03-24 University Of Maryland, Baltimore County Nanostructures for polarized imaging and receptor/ligan quantization: breaking the diffraction limit for imaging
ATE489482T1 (en) * 2005-08-19 2010-12-15 Nanosphere Inc METHOD FOR PRODUCING HYBRID SUBSTRATES WITH DNA AND ANTIBODIES AND USES THEREOF
US7736910B2 (en) * 2005-10-04 2010-06-15 Calypte Biomedical Corporation One-step production of gold sols
US20070092978A1 (en) * 2005-10-20 2007-04-26 Ronald Mink Target ligand detection
WO2007059514A2 (en) * 2005-11-15 2007-05-24 Oxonica, Inc. Sers-based methods for detection of bioagents
US7888043B2 (en) 2005-11-18 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention Modified cardiolipin and uses therefor
WO2007067999A2 (en) * 2005-12-09 2007-06-14 Amnis Corporation Extended depth of field imaging for high speed object analysis
US8409863B2 (en) 2005-12-14 2013-04-02 Becton, Dickinson And Company Nanoparticulate chemical sensors using SERS
US20090053694A1 (en) * 2005-12-26 2009-02-26 Kriksunov Leo B Photochemically Amplified Bioassay
US7723100B2 (en) 2006-01-13 2010-05-25 Becton, Dickinson And Company Polymer coated SERS nanotag
ES2601391T3 (en) * 2006-01-27 2017-02-15 Becton Dickinson And Company Side flow immunoassay with encapsulated detection mode
US8101368B2 (en) * 2006-02-13 2012-01-24 Dvs Sciences Inc. Quantitation of cellular DNA and cell numbers using element labeling
US20100060893A1 (en) * 2006-07-24 2010-03-11 Norton Scott M Assay particle concentration and imaging apparatus and method
US20090047673A1 (en) * 2006-08-22 2009-02-19 Cary Robert B Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
US7569396B1 (en) 2006-09-08 2009-08-04 Purplecow Llc Caffeine detection using internally referenced competitive assays
US7749775B2 (en) * 2006-10-03 2010-07-06 Jonathan Scott Maher Immunoassay test device and method of use
US7727776B2 (en) * 2006-10-24 2010-06-01 Honeywell International Inc. Core-shell nanoparticles for detection based on SERS
US7571695B2 (en) * 2006-11-06 2009-08-11 Temptime Corporation Freeze indicators, flexible freeze indicators and manufacturing methods
WO2008061130A2 (en) * 2006-11-15 2008-05-22 Ucp Biosciences, Inc. An improved collecting and testing device and method of use
US7919331B2 (en) * 2006-12-21 2011-04-05 Silver Lake Research Corporation Chromatographic test strips for one or more analytes
WO2008086019A1 (en) * 2007-01-09 2008-07-17 Cholestech Corporation Device and method for measuring ldl-associated cholesterol
US7776618B2 (en) * 2007-03-01 2010-08-17 Church & Dwight Co., Inc. Diagnostic detection device
EP1980853A1 (en) * 2007-04-11 2008-10-15 Alfresa Pharma Corporation Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle
US20080261328A1 (en) * 2007-04-19 2008-10-23 Alfresa Pharma Corporation Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle
ES2609818T3 (en) 2007-06-15 2017-04-24 Xiamen University Monoclonal antibodies that bind to H5 subtype avian influenza virus hemagglutinin and uses thereof
US8399261B2 (en) * 2007-06-27 2013-03-19 Inbios International, Inc. Lateral flow assay system and methods for its use
US8053203B2 (en) 2007-10-30 2011-11-08 John Wan Methods and device for the detection of occult blood
US20090196852A1 (en) * 2008-02-04 2009-08-06 Watkinson D Tobin Compositions and methods for diagnosing and treating immune disorders
US8673644B2 (en) 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
JP2010032505A (en) * 2008-06-30 2010-02-12 Arkray Inc Detection method of target substance, detection reagent used for the same, and uses thereof
US8530152B2 (en) * 2008-07-10 2013-09-10 Abaxis, Inc. Methods of reducing non-specific interaction in metal nanoparticle assays
US8383337B2 (en) * 2008-07-18 2013-02-26 General Electric Company Methods using metal oxide particles for analyte detection
US8476008B2 (en) 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
CA2742678C (en) 2008-12-03 2020-03-31 Abaxis, Inc. Lateral flow strip assay with immobilized conjugate
US8377643B2 (en) * 2009-03-16 2013-02-19 Abaxis, Inc. Split flow device for analyses of specific-binding partners
US8039272B2 (en) * 2009-04-01 2011-10-18 Nova Biomedical Rapid quantification assay involving concentrated and ligand-coated gold colloid
ES2725356T3 (en) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc ERG2 monoclonal antibodies and their therapeutic use
WO2010132447A2 (en) 2009-05-11 2010-11-18 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
EP2433132B1 (en) 2009-05-21 2018-02-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compositions and methods for the detection of hiv-1/hiv-2 infection
US8802427B2 (en) * 2009-06-09 2014-08-12 Church & Dwight Co., Inc. Female fertility test
SG176200A1 (en) * 2009-06-12 2012-01-30 Agency Science Tech & Res Method for determining protein-nucleic acid interaction
EP3109638A1 (en) 2009-08-03 2016-12-28 Yeda Research And Development Co. Ltd. Urinary biomarkers for cancer diagnosis
US8451524B2 (en) * 2009-09-29 2013-05-28 Amnis Corporation Modifying the output of a laser to achieve a flat top in the laser's Gaussian beam intensity profile
US20110151435A1 (en) * 2009-12-17 2011-06-23 Abaxis, Inc. Novel assays for detecting analytes in samples and kits and compositions related thereto
JP5831448B2 (en) * 2010-04-14 2015-12-09 日東紡績株式会社 Test instrument for measuring an analyte in a sample and method for measuring an analyte using the same
US8817115B1 (en) 2010-05-05 2014-08-26 Amnis Corporation Spatial alignment of image data from a multichannel detector using a reference image
US8945943B2 (en) 2010-05-26 2015-02-03 The Board Of Trustees Of The University Of Illinois Personal glucose meters for detection and quantification of a broad range of analytes
CA2805720A1 (en) 2010-06-17 2011-12-22 Abaxis, Inc. Rotors for immunoassays
WO2012012500A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader systems and lateral flow assays
WO2012012499A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader system
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US9410949B2 (en) 2010-12-03 2016-08-09 Washington University In St. Louis Label-free detection of renal cancer
US8703439B1 (en) 2011-01-31 2014-04-22 Linda Lester Point of care iodine sensor
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
ES2551922T3 (en) 2011-03-07 2015-11-24 Accelerate Diagnostics, Inc. Rapid cell purification systems
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
US20130171619A1 (en) 2011-12-30 2013-07-04 General Electric Company Porous membranes having a hydrophilic coating and methods for their preparation and use
EP2807271B1 (en) 2012-01-24 2018-08-22 CD Diagnostics, Inc. System for detecting infection in synovial fluid
BR112014018563A2 (en) 2012-01-31 2017-08-22 Univ Minnesota THERMAL CONTRAST TEST READER, TEST KIT, AND ANALYTES DETECTION METHOD IN A SAMPLE
US10816492B2 (en) 2012-01-31 2020-10-27 Regents Of The University Of Minnesota Lateral flow assays with thermal contrast readers
US10725033B2 (en) 2012-01-31 2020-07-28 Regents Of The University Of Minnesota Lateral flow assays with thermal contrast readers
EP2812704A4 (en) 2012-02-07 2016-03-23 Intuitive Biosciences Inc Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
US20130280696A1 (en) 2012-04-23 2013-10-24 Elliott Millenson Devices and methods for detecting analyte in bodily fluid
WO2013177473A1 (en) 2012-05-25 2013-11-28 The University Of Vermont And State Agriculture College Compositions and methods for assaying platelet reactivity and treatment selection
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
ES2761575T3 (en) 2013-01-02 2020-05-20 Qiagen Sciences Llc Methods to predict the time to delivery in a pregnant woman
EP2958584A1 (en) 2013-02-20 2015-12-30 Yeda Research and Development Co., Ltd. Interferon treatment targeting mutant p53 expressing cells
WO2014152656A1 (en) 2013-03-14 2014-09-25 Cheng Kasing Test strip housing system
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
US9383352B2 (en) 2014-03-26 2016-07-05 Diabetomics, Inc. Salivary protein glycosylation test for diagnosis and monitoring of diabetes
DK3126486T3 (en) 2014-04-02 2019-10-14 Chembio Diagnostic Systems Inc IMMUNASSAY USING THE Catch Conjugate
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
US20180011088A1 (en) 2015-01-29 2018-01-11 Neogen Corporation Methods for Immuno Chromatographic Assay Desensitization
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
KR20170132856A (en) 2015-03-30 2017-12-04 액셀러레이트 다이어그노스틱스, 아이엔씨. Instruments and systems for rapid microbiological identification and antimicrobial susceptibility testing
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
CA2983732A1 (en) 2015-04-23 2016-10-27 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Fungal detection using mannan epitope
CN108136051A (en) 2015-08-04 2018-06-08 Cd诊断股份有限公司 The method for detecting bad local organization reaction (ALTR) necrosis
AU2016340125B2 (en) 2015-10-15 2021-12-09 Inbios International, Inc. Disabled Multiplexed lateral flow assay systems and methods for their use
WO2017147186A1 (en) 2016-02-22 2017-08-31 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
US11340217B2 (en) * 2016-03-09 2022-05-24 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Catalytic particles for increased sensitivity in lateral flow immunoassays
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
WO2017178554A1 (en) 2016-04-13 2017-10-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
AU2018223316A1 (en) 2017-02-21 2019-07-25 Medicortex Finland Oy Non-invasive brain injury diagnostic device
KR102582297B1 (en) 2017-05-19 2023-09-25 필립모리스 프로덕츠 에스.에이. Diagnostic tests to distinguish a subject's smoking status
WO2019084492A1 (en) 2017-10-26 2019-05-02 Essenlix Corporation Devices and methods for monitoring liquid-solid contact time
CA3116909A1 (en) 2018-10-24 2020-04-30 Orasure Technologies, Inc. Lateral flow assays for differential isotype detection
US11300576B2 (en) 2019-01-29 2022-04-12 Arizona Board Of Regents On Behalf Of Arizona State University DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
WO2021205228A1 (en) 2020-04-07 2021-10-14 Abbott Rapid Diagnostics International Unlimited Company Assay device
WO2022090343A1 (en) 2020-10-27 2022-05-05 Ares Trading S.A. Proteins for the detection of schistosoma infection
US20230393130A1 (en) 2021-04-08 2023-12-07 Abbott Rapid Diagnostics International Unlimited Company Assay device
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection
NL2032668B1 (en) 2022-08-02 2024-02-07 Academisch Ziekenhuis Leiden Means for detecting schistosoma infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125235C (en) * 1965-04-15
US3933997A (en) * 1974-03-01 1976-01-20 Corning Glass Works Solid phase radioimmunoassay of digoxin
US4108972A (en) * 1974-03-15 1978-08-22 Dreyer William J Immunological reagent employing radioactive and other tracers
US4018886A (en) * 1975-07-01 1977-04-19 General Electric Company Diagnostic method and device employing protein-coated magnetic particles
US3970518A (en) * 1975-07-01 1976-07-20 General Electric Company Magnetic separation of biological particles
US4020151A (en) * 1976-02-17 1977-04-26 International Diagnostic Technology, Inc. Method for quantitation of antigens or antibodies on a solid surface
US4067959A (en) * 1976-05-10 1978-01-10 International Diagnostic Technology, Inc. Indirect solid surface test for antigens or antibodies
IL49685A (en) * 1976-05-31 1978-10-31 Technion Res & Dev Foundation Specific binding assay method for determining the concentration of materials and reagent means therefor
GB1582956A (en) * 1976-07-30 1981-01-21 Ici Ltd Composite magnetic particles
US4219335A (en) * 1978-09-18 1980-08-26 E. I. Du Pont De Nemours And Company Immunochemical testing using tagged reagents

Also Published As

Publication number Publication date
IL57722A0 (en) 1979-11-30
DK159799C (en) 1991-05-06
AU4883479A (en) 1980-01-17
GR73524B (en) 1984-03-09
FI77120B (en) 1988-09-30
HU181659B (en) 1983-10-28
PH16420A (en) 1983-10-03
DK159799B (en) 1990-12-03
FI792179A (en) 1980-01-14
PT69900A (en) 1979-08-01
FI77120C (en) 1989-01-10
JPS5515100A (en) 1980-02-01
DE2962333D1 (en) 1982-04-29
NL7807532A (en) 1980-01-15
IL57722A (en) 1982-09-30
DK295679A (en) 1980-01-14
AU530217B2 (en) 1983-07-07
ES482488A1 (en) 1980-08-16
EP0007654A1 (en) 1980-02-06
IE791315L (en) 1980-01-13
US4313734A (en) 1982-02-02
ZA793276B (en) 1980-07-30
EP0007654B1 (en) 1982-03-24
ATE786T1 (en) 1982-04-15
IE48467B1 (en) 1985-02-06
MX164526B (en) 1992-08-24

Similar Documents

Publication Publication Date Title
CA1135183A (en) Dispersed metal particle labelled assay
CA1143654A (en) Application of water-dispersible hydrophobic dyes as labels in immunoassays
US5514602A (en) Method of producing a metal sol reagent containing colloidal metal particles
CA1336393C (en) Test method and reagent kit therefor
US4847199A (en) Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
US4174952A (en) Immunoassay by light scattering intensity anisotropy measurements
EP0321261B1 (en) Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand
JPH0343094A (en) Extracting composition and test kit for extraction and determination of simple herpes- virus and their use
EP0321008B1 (en) Immunodetermination using non-metallic labels
JPH05310849A (en) Multifunctional, hydrophilic, spherical microparticle preparation and use thereof
EP0688428B1 (en) Immunoassay method utilizing zeta potential
JPH0827284B2 (en) Methods and reagents for measuring immunologically detectable substances
JPH0224559A (en) Measurement of immunologically detectable substance, reactor and measurement of various parameters by method by immunoassay theory
JPH02257063A (en) Reagent and method for immunoassay
JPH05232111A (en) Artificial standard and contrast serum and manufacture and use thereof
EP0280561A2 (en) Agglutination reagent and method of preparing same
JP2004117068A (en) Immunoassay reagent and immunoassay method
JP2000292424A (en) Immunity measurement method
KR930000951A (en) Diagnostic method
JP3692055B2 (en) Determination method of antigen-antibody reaction
CN115389758A (en) Colloidal gold ergosterol detection card and application thereof
JP2000221194A (en) Immunoassay
JPH03267759A (en) Immunological measurement method using immobilized red cells
JP2000206114A (en) Immunological measuring method
JP2000221193A (en) Immunoassay

Legal Events

Date Code Title Description
MKEX Expiry